

## OBSERVATIONS

## Relationship Between Periodontal Disease and Diabetic Retinopathy

Recently, various studies have reported that periodontal disease adversely affects diabetes (1). The control of periodontal disease in elderly individuals has been reported to improve the control of blood glucose (2). Severe periodontal disease is associated with elevated blood lipopolysaccharide levels as a result of periodontogenic bacteria, which induce higher levels of interleukin-6 (IL-6) and tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) (3,4). Control of periodontal disease is now considered not only a dental problem but also an issue affecting the patient's overall quality of life. Proinflammatory cytokines such as IL-6 have been shown to be involved in the pathogenesis of diabetic retinopathy (DR) (5), while the relationship between diabetic retinopathy and periodontal disease remains unclear. We investigated whether periodontal disease is correlated with diabetic retinopathy.

The study was based on a prospective review of 73 eyes in 73 consecutive diabetic patients. The mean duration of diabetes was  $14.3 \pm 7.1$  years (range 2–33), and the mean HbA<sub>1c</sub> was  $7.5 \pm 1.6\%$  (5.2–13.7). IL-6 and TNF- $\alpha$  levels in the vitreous fluid samples from 32 eyes obtained during vitrectomy and in paired plasma samples were measured by enzyme-linked immunosorbent assay. Nondiabetic patients included 10 with macular hole and 2 with epiretinal membrane. Institutional ethics committee approval was obtained, and all participants gave informed consent. The severity of diabetic retinopathy was quantified according to the modified Early Treatment Diabetic Retinopathy Study (ETDRS) retinopathy severity scale (6). The severity of periodontal disease was quantified according to bone loss and then graded and evaluated (7). Patients with periodontal disease were classified as positive or negative based on median values. Diabetic patients were classified as having nonpro-

liferative or proliferative diabetic retinopathy. Data are presented as means  $\pm$  SD. The Mann-Whitney *U* test was used to compare IL-6 and TNF- $\alpha$  levels. To determine the relationship between the severity of periodontal disease and ETDRS, retinopathy severity, or angiogenic factors, as well as between X and Y parameters, Spearman's rank-order correlation coefficient and logistic regression model were applied.

The severity of periodontal disease was significantly correlated with the severity of diabetic retinopathy ( $P = 0.0012$ ), and the risk of proliferative diabetic retinopathy was significantly higher in the presence of periodontal disease (odds ratio = 2.80,  $P = 0.036$ ). There was no significant relationship between the severity of periodontal disease and HbA<sub>1c</sub> or duration of diabetes ( $P = 0.098$  and  $0.295$ , respectively). There was a significant relationship between the severity of diabetic retinopathy and duration of diabetes ( $P = 0.002$ ). The vitreous fluid level of IL-6 (mean  $154.2 \pm 164.6$  pg/ml [range 0.993–597.0]) was significantly elevated in patients with diabetic retinopathy compared with that in nondiabetic patients (mean  $1.34 \pm 0.91$  pg/ml [0.6–3.68]) ( $P < 0.0001$ ). Furthermore, the vitreous fluid level of IL-6 was significantly correlated with the severity of periodontal disease ( $P = 0.012$ ). There was no significant relationship between the vitreous fluid level of IL-6 and HbA<sub>1c</sub> or duration of diabetes ( $P = 0.293$  and  $0.705$ , respectively). In contrast, the vitreous fluid level of TNF- $\alpha$  was not significantly correlated with the severity of periodontal disease. The IL-6 concentration in vitreous fluid (mean  $154.2 \pm 164.6$  pg/ml [0.993–597.0]) was significantly higher than that in plasma (mean  $1.89 \pm 3.47$  pg/ml [0.156–18.8]) ( $P < 0.0001$ ).

There was a significant relationship between periodontal disease and severity of diabetic retinopathy, but it was unclear whether periodontal disease directly affects the progression of diabetic retinopathy because this was a cross-sectional study. Further prospective studies, including evaluation of systemic factors, are necessary.

HIDETAKA NOMA, MD<sup>1</sup>  
IKUO SAKAMOTO, PHD<sup>1</sup>  
HIDEKI MOCHIZUKI, MD<sup>1</sup>  
HIDETOSHI TSUKAMOTO, PHD<sup>2</sup>

ATSUSHI MINAMOTO, PHD<sup>1</sup>  
HIDEHARU FUNATSU, PHD<sup>3</sup>  
HIDETOSHI YAMASHITA, PHD<sup>4</sup>  
SHIGEO NAKAMURA, PHD<sup>5</sup>  
KEN KIRIYAMA, PHD<sup>4</sup>  
HIDEMI KURIHARA, PHD<sup>5</sup>  
HIROMU K. MISHIMA, PHD<sup>1</sup>

From the <sup>1</sup>Department of Ophthalmology and Visual Science, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan; the <sup>2</sup>Department of Ophthalmology, Hiroshima Prefectural Hospital, Hiroshima, Japan; the <sup>3</sup>Department of Ophthalmology, Diabetes Center, Tokyo Women's Medical University, Tokyo, Japan; the <sup>4</sup>Department of Ophthalmology and Visual Science, Yamagata University School of Medicine, Yamagata, Japan; and the <sup>5</sup>Department of Periodontal Medicine, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan.

Address correspondence to Hiromu K. Mishima, PhD, Hiroshima University Graduate School of Biomedical Sciences, Department of Ophthalmology and Visual Science, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan. E-mail: hkmishi@hiroshima-u.ac.jp.

© 2004 by the American Diabetes Association.

### References

- Loe H: Periodontal disease: the sixth complication of diabetes mellitus. *Diabetes Care* 16:329–334, 1993
- Grossi SG, Skrepicinski FB, DeCaro T, Robertson DC, Ho AW, Dunford RG, Genco RJ: Treatment of periodontal disease in diabetics reduces glycated hemoglobin. *J Periodontol* 68:713–719, 1997
- Grossi SG, Genco RJ: Periodontal disease and diabetes mellitus: a two-way relationship. *Ann Periodontol* 3:51–61, 1998
- Soolari AS, Champagne C, Punzi JS, Amar S, Van Dyke TE: Serum modulation of neutrophil response to *Porphyromonas gingivalis* LPS in periodontal disease. *J Int Acad Periodontol* 1:101–109, 1999
- Funatsu H, Yamashita H, Shimizu E, Kojima R, Hori S: Relationship between vascular endothelial growth factor and interleukin-6 in diabetic retinopathy. *Retina* 21:469–477, 2001
- The Early Treatment Diabetic Retinopathy Study Research Group: Fundus photographic risk factors for progression of diabetic retinopathy: ETDRS report number 12. *Ophthalmology* 98:823–833, 1991
- Jeffcoat MK, Wang IC, Reddy MS: Radiographic diagnosis in periodontics. *Periodontol* 2000 7:54–68, 1995

## Effect of Diabetes Intervention Programs on Physical Activity Among Migrant Mexican Women With Type 2 Diabetes

The 2000 Dietary Guidelines for Americans and the dietary guidelines for the control of diabetes in Mexico include recommendations that adults participate in at least 30 min of moderate physical activity, preferably daily (1,2). However, to our knowledge, there have been no studies that explore the effect of diabetes intervention programs on physical activity among migrant Mexican women with type 2 diabetes.

All women from seven diabetes education groups from three different Mexican institutions located in Tijuana were invited to answer a previously validated questionnaire on physical activity. Of 111 questionnaires, 100 were adequately answered. The mean age was  $53 \pm 12$  years. The majority of the sample was migrants from other Mexican states, and 40% were classified as overweight and 31% as obese. Of the women, 62, 45, and 15% reported  $>20$ ,  $>30$ , and  $>60$  min of physical activity per day, respectively. Seventy-three percent reported  $>80$  min of weekly physical activity. Daily outdoor activity of participants was  $39 \pm 4.2$  min (mean  $\pm$  SE), and daily indoor activity was  $5.72 \pm 0.27$  h. Total light activity ( $<3.0$  metabolic equivalents [METs]) was  $5.28 \pm 0.24$  h/day, total moderate activity (3–6 METs) was  $55 \pm 14$  min/day, and total vigorous activity ( $>6.0$  METs) was  $4.2 \pm 0.6$  min/day. The average physical activity level was  $1.54 \pm 0.03$ . The main indoor activities were cooking (11 h/week), dishwashing and clothes washing (3.2 h/week), cleaning (3.1 h/week), and shopping (1.9 h/week), and the main outdoor physical activities were walking (3.1 h/week), semiactive exercise and stretching (1.26 h/week), running (0.23 h/week), and bicycle riding (0.18 h/week). The main resting activity was sleeping (49.16 h/week), followed by watching television (11.3 h/week), resting in bed (2 h/week), driving or sitting in

a car (1.5 h/week), and sitting at home (1.38 h/week).

This study shows that the majority of Mexicans with diabetes who are willing to participate in diabetes education groups at the primary health care clinics engage in  $>20$  min of daily physical activity, which therefore reinforces the need for promoting culturally based interventions (3,4). These results are better than the national data for adults with type 2 diabetes in Mexico and the U.S. (5,6); however, the groups we studied were especially motivated subjects interested in obtaining better metabolic control through diabetes education groups. On the other hand, the population from this study, which has a low socioeconomic status, usually confronts major environmental or economic barriers that prevent access to safe recreational areas or fitness facilities. Thus, even with economic constraints and inadequate environmental access to physical activity, promoting physical activity in a culturally based intervention is a worthwhile strategy that should be supported. Although further studies in large populations are still required to evaluate the effectiveness at a larger scale, at the primary care level of Mexican institutions, stronger emphasis should be placed on promoting physical activity.

MONTERRAT BACARDÍ-GASCÓN, MD  
PERLA ROSALES-GARAY, MD  
ARTURO JIMENEZ-CRUZ, MD, PHD

From the Nutrition Program, Medical School, Universidad Autonoma de Baja California, Tijuana, Mexico.

Address correspondence to Montserrat Bacardí-Gascón, MD, Universidad Autonoma de Baja California, Medical School, Nutrition, Av. Tecnológico 14418, Mesa de Otay, Baja California, Tijuana 22390, Mexico. E-mail: ajimenez@uabc.mx.

© 2004 by the American Diabetes Association.

### References

1. US Department of Agriculture/Department of Health and Human Services: Home and garden bulletin no. 232. In *2000 Dietary Guidelines for Americans*. 5th ed. Washington, DC, U.S. Department of Agriculture, 2000
2. Secretaria de Salud: *Norma Oficial Mexicana Para la Prevención, Tratamiento y Control de la Diabetes Mellitus en la Atención Primaria a la Salud*. México, DF, Mexico, Secretaria de Salud, 2000 (NOM-015-SSA2-1994)
3. Jimenez-Cruz A, Bacardí-Gascón M, Rosales-Garay P, Herrera-Espinoza J, Willis

OW: A culturally sensitive tool for Mexican people with diabetes: "La Manzana de la Salud". *Rev Biomed* 14:51–59, 2003

4. Clark DO: Physical activity efficacy and effectiveness among older adults and minorities. *Diabetes Care* 20:1176–1182
5. Aguilar-Salinas CA, Velazquez-Monroy O, Gomez-Perez FJ, Gonzalez-Chavez A, Esqueda AL, Molina-Cuevas V, Rull-Rodrigo JA, Tapia Conyer R, the Encuesta Nacional de Salud 2000 Group: Characteristics of patients with type 2 diabetes in Mexico: results from a large population-based nationwide survey. *Diabetes Care* 26:2021–2026, 2003
6. Nelson KM, Reiber G, Boyko EJ: Diet and exercise among adults with type 2 diabetes. *Diabetes Care* 25:1722–1728, 2002

## Alternative Site Testing at the Earlobe Tip

Reliability of glucose measurements and pain perception

There is growing interest in alternative less painful sites for capillary blood glucose (CBG) monitoring. The earlobe tip is a potential site (1) that has been occasionally used by nurses when fingertip testing is refused or difficult. We investigated the clinical value and accuracy of earlobe CBG measurements as an alternative to fingertip and forearm testing.

A total of 50 patients with type 2 diabetes (aged 42–82 years, 28% with neuropathy) were enrolled in the study. The duration of diabetes was  $9.5 \pm 8.3$  years (means  $\pm$  SD). Testing sites (lateral aspect of the fingertip, earlobe tip, and flexor surface of the forearm) were rubbed and cleaned before lancing was performed by a physician using Lifescan Unistick-2 lancets (Lifescan, Milpitas, CA). The forearm was lanced using the Microlet-Vaculance device (Bayer, Tarrytown, NY). The order of site testing was randomized. Pain was immediately assessed after the first attempt using a 100-mm graphic visual scale (2). CBG was measured with an Accu-Check Advantage glucose meter (Roche, Indianapolis, IN).

First-attempt sampling success rates were 88% (fingertip), 74% (earlobe), and

62% (forearm). After earlobe pricking, bleeding lasted for <60 s in all subjects (<30 s in 90%). Earlobe pain (median score 5.5 mm) was less uncomfortable than fingertip pain (17 mm,  $P < 0.01$ , Wilcoxon test) but not statistically different from forearm (8.0 mm). Although earlobe pain was more tolerable, a limitation in this study is that it did not evaluate pain perception after repeated testing on multiple days, when skin soreness might become relevant.

CBG measurements from the earlobe deviated from the fingertip by  $9.5 \pm 1.0\%$  (mean  $\pm$  SE). The correlation coefficient between these two sites was 0.97 ( $P < 0.01$ ). Of earlobe measurements, 97.8% were within clinically acceptable zones A+B by error grid analysis (3). When earlobe was compared with forearm, CBG deviation was  $10 \pm 1.4\%$ , correlation coefficient 0.96 ( $P < 0.01$ ), and 95.3% of measurements were within zones A+B by error grid analysis.

In contrast to other sites that require vacuum-assisted lancing devices or sophisticated glucose meters, our observations demonstrate that CBG monitoring at the earlobes is attainable with regular standard lancets and that earlobe CBG concentrations correlate well and deviate minimally from either fingertip or forearm values. Earlobe testing was also clinically accurate by the error grid analysis method, which takes into account the effects on the clinical decision that would have been made if the CBG had been measured in the reference site. These data support the notion that earlobe CBG concentrations can be used in substitution of fingertip values. However, one limitation in our data series is that glucose values <70 mg/dl were not observed. Therefore, earlobe testing should be avoided if hypoglycemia is suspected.

For many patients, the earlobe pricking technique may be less convenient because it requires a second person to lance the skin and collect the blood. This certainly limits the applicability of the technique in the outpatient setting. Nevertheless, earlobe testing seems to be a useful alternative that could minimize costs and discomfort in patients assisted by a relative or nurse in hospitals and nursing homes.

FREDERICO G.S. TOLEDO, MD<sup>1,2</sup>  
ANDREW TAYLOR, MD<sup>2</sup>

From the <sup>1</sup>Department of Medicine, Division of Endocrinology and Metabolism, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; and the <sup>2</sup>Department of Internal Medicine, Division of Endocrinology and Metabolism, University of Miami School of Medicine and Miami VA Medical Center, Miami, Florida.

Address correspondence to Frederico G.S. Toledo, MD, University of Pittsburgh Medical Center, Department of Medicine, Division of Endocrinology and Metabolism, E1140 Biomedical Science Tower, 200 Lothrop St., Pittsburgh, PA 15261. E-mail: toledofs@msx.upmc.edu.

© 2004 by the American Diabetes Association.

## References

1. Carley SD, Libetta C, Flavin B, Butler J, Tong N, Sammy I: An open trial to reduce the pain of blood glucose testing: ear versus thumb. *BMJ* 321:20, 2000
2. Huskisson EC: Measurement of pain. *Lancet* 9:1127–1131, 1974
3. Clarke WL, Cox D, Gonder-Frederick LA, Carter W, Pohl SL: Evaluating clinical accuracy of systems for self-monitoring of blood glucose. *Diabetes Care* 10:622–628, 1987

## Needle Reuse and Tip Damage

Questions about needle reuse are raised in recommendations by the American Diabetes Association (1) and by practitioners and manufacturing companies (2). As an initial approach to examining these questions, we investigated whether multiple insertions of needles through the rubber stoppers on insulin vials would cause damage to needle tips (3). New needles were selected, attached to a precision manipulator, and inserted into insulin vials attached to a transducer that measured the force necessary to insert and remove a needle through the stopper. If needles were damaged by multiple insertions, an increase in force required to penetrate the rubber stopper would be expected.

In five experiments, we found that there was no significant difference in the mean force required to penetrate the rubber stopper of an insulin vial between 17 initial (41.5 g) and 17 subsequent (42.0 g) insertions. This suggests that needle tips are not dulled or damaged by multiple insertions to a degree that more force would be required to penetrate a vial

stopper. Light micrographs and scanning electron micrographs supported the conclusion that little or no damage to needle tips occurred as a result of multiple insertions. We observed no hooks, bending, or other needle tip damage, although there was some evidence for deterioration of the silicon lubricant coating of needles.

At the same time, our examination of new, unused needles revealed imperfections when observed at high magnification. Our observations make it clear that damage attributed to reuse must be distinguished from inherent imperfections associated with the manufacturing process.

Clinical and manufacturer recommendations that discourage reuse of needles because of assumed dulling, bending, and/or fragmenting of needle tips are at variance with our findings, in which repeated penetration of insulin vial stoppers did not damage needle tips (2). Although we found no evidence of needle damage when penetrating the rubber stopper on insulin vials, there is need to ascertain the effect of cutaneous tissue penetration on needle tips. The reuse of needles by a significant number of patients with diabetes as a matter of convenience, or out of concern for cost and/or the creation of nonbiodegradable waste, indicates that further examination of needle reuse in vial stoppers and cutaneous tissue is warranted.

DOUGLAS KLINE, PHD<sup>1</sup>  
TERRY KUHN, PHD<sup>2</sup>

From the <sup>1</sup>Department of Biological Sciences, Kent State University, Kent, Ohio; and the <sup>2</sup>Division of Undergraduate Studies, Kent State University, Kent, Ohio.

Address correspondence to Terry Kuhn, Kent State University, Division of Undergraduate Studies, P.O. Box 5190, Kent, OH 44242-0001. E-mail: tkuhn@kent.edu.

© 2004 by the American Diabetes Association.

## References

1. American Diabetes Association: *American Diabetes Association Complete Guide to Diabetes*. 3rd ed. American Diabetes Association, Alexandria, VA, 2002, p. 106, 480
2. Effect of multiple insulin vial insertions on needle tips [article online], 2003. Available from <http://www.diabetesneedlereuse.org>. Accessed 8 December 2003
3. The Editors: Questions and answers (Letter). *Diabetes Self Manag* 17:94–95, 2000

## The Diabetes Treatment Satisfaction Questionnaire

A cross-cultural South African perspective

**R**eliable and valid multicultural instruments are important in multicultural societies that are typical of modern cities, and clinicians, using psychosocial assessments, need to ensure that their diagnostic and screening tools are appropriate. This study was conducted with 176 diabetic outpatients from two culturally distinct groups (95 Bantu-speaking and 81 Afrikaans-speaking subjects) to 1) ascertain the underlying dimensions of treatment satisfaction as measured by the Diabetes Treatment Satisfaction Questionnaire (DTSQ status) (1), 2) determine the reliability (internal consistency) of the measures, and 3) investigate the effects of objective (HbA<sub>1c</sub> results) and subjective metabolic control, health (2), and well-being (3) on satisfaction with diabetes treatment.

Principal components analysis was conducted on the 8-item DTSQ (1). All communality estimates exceeded the criterion of 0.30 (4) for both Bantu-speaking and Afrikaans-speaking patients (range 0.62–0.79 and 0.55–0.76, respectively). Two factors explained 71% of the variance for Bantu-speaking patients and 68% of the variance for Afrikaans-speaking patients. The first factor consisted of the six treatment satisfaction items, and the second factor consisted of the two subjective metabolic control items. Reliability (internal consistency) coefficients were excellent (5) and very similar for both groups (>0.80 on all measures).

Treatment satisfaction was associated with fewer incidents of hyperglycemia ( $r = -0.58, P < 0.01$ ) and hypoglycemia ( $r = -0.32, P < 0.01$ ), higher general well-being ( $r = 0.56, P < 0.01$ ), and better health ( $r = 0.44, P < 0.01$ ) for Bantu-speaking patients. For Afrikaans-speaking patients, greater treatment satisfaction was associated with fewer incidents of hyperglycemia ( $r = -0.29, P < 0.01$ ), higher general well-being ( $r =$

0.54,  $P < 0.01$ ), and better health ( $r = 0.50, P < 0.01$ ). Language, sex, age, and employment status were not related to treatment satisfaction or general well-being ( $P > 0.05$ ), confirming the construct validity of the measures. HbA<sub>1c</sub> results were not significantly related to treatment satisfaction, subjective metabolic control, general well-being, or general health for either group ( $P > 0.05$ ).

For Bantu-speaking patients, fewer incidents of hyperglycemia significantly predicted 33% of the variance ( $P < 0.001$ ) in treatment satisfaction; an additional 11% of the variance ( $P < 0.001$ ) was explained by general well-being. For Afrikaans-speaking patients, general well-being predicted 29% of the variance ( $P < 0.001$ ) in treatment satisfaction; an additional 7% of the variance ( $P = 0.001$ ) was explained by general health.

In conclusion, the study demonstrated that the underlying dimensions of the DTSQ for both groups were treatment satisfaction and hyper- and hypoglycemia, all measures had excellent reliability (5), and well-being is an important predictor of treatment satisfaction for both groups of patients. These findings were consistent with those reported in the U.K. and Sweden (6–7) and support the idea that the DTSQ can be used in multicultural settings.

**Acknowledgments**—We thank Novo Nordisk (South Africa) for funding the interviewers' salaries. We also thank Professor Clare Bradley for permission to use her measures and Rosalind Plowright for constructive comments on the application of the DTSQ in multicultural settings.

MARGARET SANDRA WESTAWAY, PHD<sup>1,2</sup>  
JOHN R. SEAGER, PHD<sup>1,3</sup>

From the <sup>1</sup>South Africa Medical Research Council, Health and Development Research Group, Pretoria, Gauteng, South Africa; the <sup>2</sup>School of Health Systems and Public Health, University of Pretoria, Pretoria, Gauteng, South Africa, and the <sup>3</sup>Faculty of Community and Health Sciences, University of the Western Cape, Cape Town, Western Cape, South Africa.

Address correspondence to Prof. Margaret Sandra Westaway, SA Medical Research Council, Health and Development Department, Private Bag X385, Pretoria, Gauteng, 0001 South Africa. E-mail: margaret.westaway@mrc.ac.za.

© 2004 by the American Diabetes Association.

### References

- Bradley C: Diabetes treatment satisfaction questionnaire. In *Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice*. Bradley C, Ed. Chur, Switzerland, Harwood Academic, 1994, p. 111–132
- Stewart AL, Hays RD, Ware JE: The MOS Short-Form General Health Survey: reliability and validity in a patient population. *Med Care* 26:724–735, 1988
- Bradley C: The well-being questionnaire. In *Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice*. Bradley C, Ed. Chur, Switzerland, Harwood Academic, 1994, p. 89–109
- Child D: *The Essentials of Factor Analysis*. London, Holt, Rinehart & Winston, 1970, p. 33–34
- Arias E, de Vos S: Using housing items to indicate socio-economic status: Latin America. *Soc Indic Res* 38:53–80, 1996
- Petterson T, Young B, Lee P, Newton P, Hollis S, Dornan T: Well-being and treatment satisfaction in older people with diabetes. *Diabetes Care* 21:930–935, 1998
- Wredling R, Stålhammar J, Adamson U, Berne C, Larsson Y, Östman J: Well-being and treatment satisfaction in adults with diabetes: a Swedish population-based study. *Qual Life Res* 4:515–522, 1995

## Depression, Diabetes, and Glycemic Control in Pima Indians

**F**ew studies have addressed the relationship of depression and diabetes in ethnic minority groups, especially Native Americans (1). We examined the relationship between depression and diabetes in a community-based sample of 541 Pima Indians aged  $\geq 18$  years (192 with and 349 without diabetes) examined from September 2002 through February 2003.

Depression was defined by five or more depressive symptoms lasting  $\geq 2$  weeks, as assessed with PRIME-MD (Mood Module in the Primary Care Evaluation of Mental Disorders) (2). Diabetes was defined by a glucose tolerance test (fasting plasma glucose  $\geq 7.0$  mmol/l or 2-h plasma glucose  $\geq 11.1$  mmol/l) or previous clinical diagnosis.

The prevalence of depression was 16.3% (18.7% in women and 12.6% in men,  $P = 0.06$ ). In both sexes, the prevalence of depression was higher in diabetic individuals (men 17.2 vs. 10.9%, women 20.2 vs. 17.6%), although these differences were not statistically significant (for total sample: age- and sex-adjusted odds ratio 1.3 [95% CI 0.7–2.1]). In diabetic individuals, HbA<sub>1c</sub> was higher by 1.2% in those with depression (9.3 vs. 8.1%,  $P < 0.01$ ), although depression was not related to HbA<sub>1c</sub> in nondiabetic individuals (5.2 vs. 5.3%,  $P = 0.2$ ). This association remained significant in a multivariate linear regression model that included age, sex, duration of diabetes, and BMI (HbA<sub>1c</sub> higher by 1.1% in depressed persons,  $P = 0.01$ ). Fasting plasma glucose was also higher, but not significantly so, in depressed diabetic individuals (10.2 vs. 9.5 mmol/L,  $P = 0.3$ ).

Although studies of depression in Native-American communities are limited, our findings are consistent with previous suggestions that depression is several times more prevalent among Native Americans than in the general U.S. population (3). Our finding that the prevalence of depression was somewhat higher in diabetic individuals is also consistent with previous studies (1,4–6). Our study lacks precision to estimate the association of depression with diabetes because of the relatively small sample size (541, as compared with 21,513 to 1.3 million in other recent reports [4–6]). The high prevalence of depression in our study suggests that certain social, cultural, or economic factors may overshadow the influence of diabetes on depression in this population.

The higher HbA<sub>1c</sub> in depressed diabetic individuals is consistent with previous findings in other populations (7). Treatment of depression reportedly improves glycemic control in diabetic patients, although the long-term effects are not known (8,9). This study adds to the sparse literature on depression and diabetes in ethnic minority groups. Identification and treatment of depression may be an important aspect of treating diabetes in Native Americans.

PUNEET K. SINGH, BA  
HELEN C. LOOKER, MBBS  
ROBERT L. HANSON, MD, MPH  
JONATHAN KRAKOFF, MD  
PETER H. BENNETT, MB, FRCP  
WILLIAM C. KNOWLER, MD, DRPH

From the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona.

Address correspondence to Helen C. Looker, National Institutes of Health, 1550 E. Indian School Rd., Phoenix, AZ 85014. E-mail: hlooker@mail.nih.gov.

© 2004 by the American Diabetes Association.

**Acknowledgments**—We thank Dr. Richard Rubin, Dr. Patrick Lustman, and Dr. Mary de Groot for advice; Dr. Diane Montella and Priscilla Foote, MSW, of Gila River Health Care; and the members of the Gila River Indian Community for their participation.

#### References

1. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ: The prevalence of comorbid depression in adults with diabetes: a meta-analysis. *Diabetes Care* 24:1069–1078, 2001
2. Spitzer RL, Williams JB, Kroenke K, Linzer M, deGruy FV III, Hahn SR, Brody D, Johnson JG: Utility of a new procedure for diagnosing mental disorders in primary care: the PRIME-MD 1000 study. *JAMA* 272:1749–1756, 1994
3. US Department of Health and Human Services: Mental health. A supplement to *Mental Health: A Report of the Surgeon General: Culture, Race, and Ethnicity*. Rockville, MD, U.S. Department of Health and Human Services, 2001
4. Egede LE, Zheng D, Simpson K: Comorbid depression is associated with increased health care use and expenditures in individuals with diabetes. *Diabetes Care* 25:464–470, 2002
5. Nichols GA, Brown JB: Unadjusted and adjusted prevalence of diagnosed depression in type 2 diabetes. *Diabetes Care* 26:744–749, 2003
6. Finkelstein EA, Bray JW, Chen H, Larson MJ, Miller K, Tompkins C, Keme A, Manderscheid R: Prevalence and costs of major depression among elderly claimants with diabetes. *Diabetes Care* 26:415–420, 2003
7. Lustman PJ, Anderson RJ, Freedland KE, de Groot M, Carney RM, Clouse RE: Depression and poor glycemic control: a meta-analytic review of the literature. *Diabetes Care* 23:934–942, 2000
8. Lustman PJ, Freedland KE, Griffith LS, Clouse RE: Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. *Diabetes Care* 23:618–623, 2000
9. Lustman PJ, Griffith LS, Freedland KE, Kissel SS, Clouse RE: Cognitive behavior therapy for depression in type 2 diabetes mellitus: a randomized, controlled trial. *Ann Intern Med* 129:613–621, 1998

## Improper Insulin Compliance May Lead to Hepatomegaly and Elevated Hepatic Enzymes in Type 1 Diabetic Patients

We have encountered hepatomegaly and pronounced elevation of liver enzymes AST and ALT in four patients with type 1 diabetes. These patients shared similar clinical features. They were all female (aged 11–14 years) with poor glycemic control. All had frequent hyperglycemia and intermittent hypoglycemia related to their history of poor compliance. Most of them had multiple hospital admissions for severe hyperglycemia and/or diabetic ketoacidosis. In addition to their high daily doses of insulin (1.3–2.2 units · kg<sup>-1</sup> · day<sup>-1</sup>), most were receiving extra doses of insulin to correct their frequent hyperglycemia. A1C levels were all higher than normal (ranging from 9.2 to 14.5%). Their initial AST and ALT levels were at least 30- and 14-fold higher than the normal limits, respectively, but the other liver function tests, such as alkaline phosphatase, prothrombin/partial prothrombintime, and total bilirubin, were normal except for one patient who had a minimal increase in alkaline phosphatase and total bilirubin. The degree of hepatomegaly did not correlate with the liver enzyme levels, nor did it correlate with glycemic control or HbA<sub>1c</sub> levels.

Upon admission to the hospital, proper insulin dosing was established. Three of the four patients were able to lower their insulin dose to 0.9–1.2 units · kg<sup>-1</sup> · day<sup>-1</sup> and achieve normal glycemic control. The AST and ALT levels were quickly decreased in just a few days after the patients obtained better glycemic control during hospitalization. Except for one patient, who was admitted for diabetic ketoacidosis, the patients had no apparent symptoms of liver disease before the admission. Their hepatomegaly was an incidental finding. Other than poorly controlled diabetes, the investigations did not reveal any other causes for hepatomegaly and increased liver enzymes. The normal creatine phosphokinase level and negative

myoglobinuria from one patient ruled out the possibility of rhabdomyolysis. The liver biopsy obtained in one patient revealed abundant glycogen deposits in hepatocytes that were consistent with the abdominal computed tomography finding of "fatty" appearance of those enlarged livers in all four patients. There were also some features that these patients did not share. One patient with the most profound hepatomegaly had significant delay in growth and puberty consistent with Mauriac syndrome as previously described (1), whereas the other three patients had normal growth and puberty. One patient, who was found to have hepatomegaly and elevated hepatic enzymes during one of her admissions to the hospital for diabetic ketoacidosis, had some nonspecific gastrointestinal symptoms that might have been related to her diabetic ketoacidosis rather than the hepatic disorder. Although all of our cases were girls, similar cases have been identified in boys (2).

Hepatomegaly and elevated hepatic enzymes, reported in both adult and pediatric patients with type 1 diabetes (2,3), could be relatively common but may be under-recognized or misidentified as the more common nonalcoholic steatohepatitis (NASH) because of similar clinical features. NASH is commonly seen in obese type 2 diabetic patients with insulin resistance. The hepatic enzyme elevation is slow to resolve. Our patients, however, were all nonobese type 1 diabetic patients. Their pronounced elevation of hepatic enzymes was resolved in just a few days once they achieved reasonable glycemic control at insulin dosages that were lower than what they were prescribed at home. Though the mild hepatomegaly and abnormal liver enzymes were believed to be associated with liver steatic change in NASH, whether the pronounced elevation of the liver enzymes was directly caused by liver glycogen deposit is not known. The pathogenesis for these problems has not been well studied. Nevertheless, both the increased hepatic enzymes and glycogen deposits may be related to poor glycemic control. Most of our patients received relatively high doses of insulin at home. We question the possible role of insulin over-treatment that might contribute to the pathogenesis of hepatomegaly because insulin is clearly a promoting agent for glycogenesis. Similar cases of hepatomegaly and elevated

hepatic enzymes have been reported in children and adolescents who were chronically over-treated with insulin (4,5).

We therefore advocate the high vigilance in promoting patient compliance to insulin dosing rather than simply increasing insulin dosage in response to hyperglycemia. The swift reduction of hepatic enzymes in our cases after achieving reasonable glycemic control suggests that liver biopsy and other extensive work-up may be unnecessary in managing similar patients.

Y. MILES YU, MD  
CAMPBELL P. HOWARD, MD

From the Section of Endocrinology, Children's Mercy Hospital, University of Missouri at Kansas City School of Medicine, Kansas City, Missouri.

Address correspondence to Miles Yu, Section of Endocrinology, Children's Mercy Hospital, 2401 Gillham Rd., Kansas City, MO 64108. E-mail: milesyu@cmh.edu.

© 2004 by the American Diabetes Association.



#### References

1. Lee RGG, Bode HH: Stunted growth and hepatomegaly in diabetes mellitus. *J Pediatr* 91:82–84, 1977
2. Chatila R, West AB: Hepatomagely and abnormal liver tests due to glycogenesis in adults with diabetes. *Medicine* 75:327–333, 1996
3. Olssen R, Wesslau C, William-Olsen T, Zettergren L: Elevated aminotransferases and alkaline phosphatases in unstable diabetes mellitus without ketoacidosis or hypoglycemia. *J Clin Gastroenterol* 11: 541–545, 1989
4. Asherov J, Mimouni M, Varsano I, Lubin E, Laron Z: Hepatomagely due to self-induced hyperinsulinism. *Arch Dis Child* 54: 148–149, 1979
5. Rosenbloom AL, Giordano BP: Chronic overtreatment with insulin in children and adolescents. *Am J Dis Child* 131:881–885, 1977

## Acute Hyperglycemia

Implications for contrast-induced nephropathy during cardiac catheterization

**A**cute hyperglycemia exacerbates ischemic injury of the brain and heart (1,2). Renal contrast agents are nephrotoxic, largely due to acute isch-

emia secondary to renal artery vasoconstriction (3). Historically, diabetic patients have been identified as a high-risk group for the development of contrast-induced nephropathy following cardiac catheterization; however, the mechanism for this increased risk is unclear (4). The purpose of this study was to determine whether acute hyperglycemia is an independent risk factor for the development of contrast-induced nephropathy after cardiac catheterization procedures.

A prospective, observational study was performed on all patients with diabetes (insulin dependent and independent) or any patient with a baseline serum creatinine  $\geq 1.2$  mg/dl receiving a cardiac catheterization procedure in a university-affiliated cardiac catheterization facility between June 2001 and January 2002. Patients with a diagnosis of acute renal failure or patients on dialysis were excluded. Patients were divided into two groups, hyperglycemic (AHG) (serum glucose  $\geq 150$  mg/dl) and nonhyperglycemic (NHG) (serum glucose  $< 150$  mg/dl), at the time of cardiac catheterization procedures. Contrast-induced nephropathy was defined as an increase in serum creatinine  $\geq 0.3$  mg/dl or  $> 25\%$  above the patient's baseline, determined 3–5 days following cardiac catheterization procedures.

The mean age, baseline creatinine, presence or absence of diabetes, hydration status, type and dose of contrast agent received, and use of specific medications, including acetylcysteine, were not different between groups. The percentage of inpatients was greater in the AHG group (74%) than in the NHG (26%),  $P = 0.049$ . Ventricular function, as measured by left ventricular end-diastolic pressure, was the same between groups (AHG =  $17 \pm 10$  mmHg vs. NHG =  $13 \pm 3$  mmHg,  $P = 0.21$ ), and left ventricular ejection fraction was significantly lower in the AHG group (AHG =  $45 \pm 13\%$  vs. NHG =  $59 \pm 14\%$ ,  $P = 0.023$ ). A total of 38 patients were studied, including 33 diabetic subjects (87%). One-half of the study group (19 patients) was found to have hyperglycemia at the time of their cardiac catheterization procedure. Mean serum glucose was  $217 \pm 78$  mg/dl for the AHG group vs.  $124 \pm 15$  mg/dl for the NHG group,  $P < 0.001$ . The incidence of contrast-induced nephropathy for the entire study

population was 24% (9 of 38). The incidence of contrast-induced nephropathy in the AHG group was 42% (8 of 19) and was significantly greater than that for the NHG group, 5.3% (1 of 19),  $P = 0.01$ .

Acute hyperglycemia is a potential independent risk factor for the development of contrast-induced nephropathy in diabetic patients undergoing cardiac catheterization procedures. The glucose molecule has been shown to be a potential cytotoxin in the context of hyperglycemia (5). Acute hyperglycemia in patients with or without diabetes can detract from clinical outcomes in cardiovascular disease (1). The mechanism by which acute hyperglycemia worsens ischemic myocardial injury is currently under study. Conceivably, hyperglycemia may exacerbate acute renal ischemia associated with administration of radiographic contrast agents. The observational design of this study limits the relationship between acute hyperglycemia and contrast-induced nephropathy to that of a temporal association and does not address causality. Confounding variables, such as the slightly worse left ventricular ejection fraction in the AHG group, may have contributed to the development of contrast-induced nephropathy; however, the hyperglycemia in the AHG group may have contributed to poorer ventricular function. The relationship between acute hyperglycemia and contrast-induced nephropathy reported here will require a randomized controlled clinical trial for definitive characterization. This report suggests that a temporal association exists between acute hyperglycemia and contrast-induced nephropathy at the time of cardiac catheterization procedures in diabetic patients with mild renal dysfunction, and this topic bears further study.

DIANE B. TURCOT, MD<sup>1</sup>

FRANCIS J. KIERNAN, MD, FACC<sup>1</sup>

RAYMOND G. MCKAY, MD, FACC<sup>1</sup>

NEIL J. GREY, MD, FACP<sup>2</sup>

WILLIAM BODEN, MD, FACC<sup>1</sup>

GEORGE A. PERDRIZET, MD, PHD, FACS<sup>3</sup>

From the <sup>1</sup>Division of Cardiology, Hartford Hospital, University of Connecticut School of Medicine, Hartford, Connecticut; the <sup>2</sup>Division of Endocrinology, Hartford Hospital, University of Connecticut School of Medicine, Hartford, Connecticut; and the <sup>3</sup>Division of Trauma, Hartford Hospital, University of Connecticut School of Medicine, Hartford, Connecticut.

Address correspondence to George A. Perdrizet, MD, PhD, FACS, Hartford Hospital, Division of

EMS/Trauma, 80 Seymour St., P.O. Box 5037, Hartford, CT 06102-5037. E-mail: gperdrizet@hartosp.org.

© 2004 by the American Diabetes Association.

#### References

1. Malmberg K, for the DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group: Prospective randomized study of intensive insulin treatment on long-term survival after acute myocardial infarction in patients with diabetes mellitus. *BMJ* 314:1512-1515, 1997
2. Weir CJ, Murray GD, Dyker AG, Lees KR: Is hyperglycemia a predictor of poor outcome after acute stroke? *BMJ* 314:1303-1306, 1997
3. Brezis M, Rosen S: Hypoxia of the renal medulla: its implication for disease. *N Engl J Med* 332:647-655, 1995
4. Parfrey PS, Griffiths SM, Barrett BJ, Paul MD, Genge M, Withers J, Farid N, McManamon PJ: Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both: a prospective controlled study. *N Engl J Med* 320:143-149, 1989
5. Porte D Jr, Schwartz MW: Diabetes complications: why is glucose potentially toxic? *Science* 272:699-700, 1996

## Influence of the Polymorphisms Trp64Arg in the $\beta$ 3-Adrenergic Receptor Gene and Pro12Ala in the PPAR $\gamma$ 2 Gene on Metabolic Syndrome-Related Phenotypes in an Indigenous Population of the Brazilian Amazon

Metabolic syndrome is a cluster of risk factors for type 2 diabetes and cardiovascular disease. Multiple mechanisms, including genetic factors, may contribute to this condition. The Trp64Arg variant in the  $\beta$ 3-adrenergic receptor has been associated with features of the metabolic syndrome (1). A relatively common gene variant, Pro12Ala of the peroxisome proliferator-activated receptor- $\gamma$ 2 (PPAR $\gamma$ 2) has been previously

studied for association with obesity and type 2 diabetes (2,3).

The Parkataje Indians, from the Brazilian Amazon region, remained largely isolated. Recently, they underwent a rapid and intensive process of acculturation, with important changes in their lifestyle. Accompanying these changes, an increasing prevalence of obesity and other features of the metabolic syndrome have been observed. This study examines the relevance of the Trp64Arg mutation in the  $\beta$ 3-adrenergic receptor gene and the Pro12Ala mutation in the PPAR $\gamma$ 2 gene as a susceptibility factor to features of the metabolic syndrome in this population.

Participants were individuals aged  $\geq 20$  years; those with admixture and pregnant women were excluded. The study population comprised 85 (52 men and 33 women) individuals (mean age  $41 \pm 14.9$  years). The degree of relatedness among the individuals was determined, and 37 nuclear families from six pedigrees were verified. Polygamy, including polyandry, occurs in this population. BMI, waist-to-hip ratio, systolic and diastolic blood pressures, and serum lipoproteins were studied. Fasting and 2-h blood samples were drawn for glucose and insulin measurements. Changes in body weight were analyzed in 80 individuals for a 3-year period. Genotypes were determined by PCR/restriction fragment-length polymorphism, as previously described (1,2).

A principal component analyses from the correlation matrix of the variables measured was performed. Statistical analyses (ANOVA and family-based association test) were done with the first two principal components because the measured variables are all related to the metabolic syndrome. The principal component, therefore, reflects the variance common to these variables and avoids corrections for multiple independent tests.

Obesity rates were higher in women than in men (27.2 vs. 3.8% at baseline,  $P = 0.006$  and 45.2 vs. 16.3% at 3-year follow-up,  $P = 0.01$ ), and for both sexes, there was an increase in these rates during the follow-up period (12.94 vs. 27.5%,  $P = 0.03$ ). Diabetes was diagnosed in one individual, impaired glucose tolerance in another, and the remaining were classified as normal glucose tolerant according to World Health Organization criteria.

Frequencies of the  $\beta$ 3-adrenergic re-

ceptor Arg and the PPAR $\gamma$ 2 Ala variants were 0.33 and 0.31, respectively. These frequencies are in the Hardy-Weinberg equilibrium. The  $\beta$ 3-adrenergic receptor Arg allele frequency (0.33) is much higher than those reported in other populations, except for Pima Indians (4). Similarly, the PPAR $\gamma$ 2 Ala allele was more prevalent in the Parkateje Indians than in the other populations, whose frequency ranges from 0.12 among Caucasians to 0.01 in Chinese (5). ANOVA (with Welch's correction) showed that the first principal component was heterogeneous among the genotypic classes of the PPAR $\gamma$ 2 locus; the AlaAla genotype was different from the others ( $F = 3.51$ ,  $P = 0.035$ ). The  $\beta$ 3-adrenergic receptor locus showed no differences among the genotypes. The FBAT analyses showed that the PPAR $\gamma$ 2 locus presented a significant segregation distortion with the recessive model ( $P = 0.032$ ) but not with the additive or dominant models.

Among the Parkateje Indians, the Pro12Ala variant in the PPAR $\gamma$ 2 gene, but not the Trp64Arg variant in the  $\beta$ 3-adrenergic receptor, was associated with features of the metabolic syndrome.

JOAO PAULO B. VIEIRA-FILHO, MD, PHD<sup>1</sup>  
 ANDRE F. REIS, MD, PHD<sup>1</sup>  
 TERESA S. KASAMATSU, BSC<sup>1</sup>  
 EDELWEISS F. TAVARES, MD, PHD<sup>1</sup>  
 LAERCIO J. FRANCO, MD, PHD<sup>2</sup>  
 SERGIO R. MATIOLI, PHD<sup>3</sup>  
 REGINA S. MOISES, MD, PHD<sup>1</sup>

From the <sup>1</sup>Division of Endocrinology, Department of Medicine, Federal University of São Paulo, São Paulo, Brazil; the <sup>2</sup>Department of Social Medicine, Faculty of Medicine of Ribeirão Preto-University of São Paulo, São Paulo, Brazil; and the <sup>3</sup>Department of Biology, University of São Paulo, São Paulo, Brazil.

Address correspondence to Regina S. Moises, MD, PhD, Universidade Federal de São Paulo, Escola Paulista de Medicina, Disciplina de Endocrinologia, Rua Botucatu, 740-2<sup>o</sup>, andar, 04034-970 São Paulo, SP, Brazil. E-mail: rmoises@endocrino.epm.br.

© 2004 by the American Diabetes Association.

## References

1. Widén E, Lehto M, Kanninen T, Walston J, Shuldiner AR, Groop LC: Association of a polymorphism in the  $\beta$ 3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. *N Engl J Med* 333:348–351, 1995
2. Ek J, Urhammer SA, Sorensen TIA, Andersen T, Auwerx J, Pedersen O: Homozygosity of the Pro12Ala variant of the

peroxisome proliferation-activated receptor- $\gamma$ 2 (PPAR- $\gamma$ 2): divergent modulating effects on body mass index in obese and lean Caucasian men. *Diabetologia* 42:892–895, 1999

3. Altshuler D, Hirschhorn JN, Klannermark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L, Lander ES: The common PPAR gamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. *Nat Genet* 26:76–80, 2000
4. Walston J, Silver K, Bogardus C, Knowler WC, Celli FS, Austin S, Manning B, Strosberg AD, Stern MP, Raben N, Sorkin JD, Roth J, Shuldiner AR: Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the  $\beta$ 3-adrenergic-receptor gene. *N Engl J Med* 333:347–347, 1995
5. Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yamall DP, Burns DK, Roth J, Shuldiner AR: Molecular scanning of the human peroxisome proliferator activated receptor gamma gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. *Biochem Biophys Res Commun* 241:270–274, 1997

## Elevated Serum Ferritin Concentrations in a Glucose-Impaired Population and in Normal Glucose Tolerant First-Degree Relatives in Familial Type 2 Diabetic Pedigrees

Two large epidemiological studies have recently reported a strong association between elevated serum ferritin concentration and increased risk for diabetes (1,2). Moreover, other studies have revealed the relationship among excess ferritin, coronary heart disease, and insulin resistance and have therefore renewed interest in ferritin as a risk factor for diabetes.

This study further investigates the association between ferritin metabolism and different status of glucose tolerance, including 121 type 2 diabetic subjects, 86 impaired glucose tolerant (IGT) subjects, 58 normal glucose tolerant (NGT) first-

degree relatives in type 2 diabetic pedigrees, and 85 healthy control subjects. All patients underwent an oral glucose tolerance test (OGTT) and insulin release tests after 8 h of fasting, and blood levels of ferritin, HbA<sub>1c</sub>, glucose, insulin, C-peptide, and lipids were measured. Serum ferritin levels were measured with the radioimmunoassay kit (Beijing North Institute of Biological Technology). Normal ranges for ferritin concentration are ~12–245 ng/ml for adult men and ~5–130 ng/ml for women. We defined elevated concentrations of ferritin as  $\geq 295$  ng/ml for men and  $\geq 155$  ng/ml for women.

Levels of fasting and postprandial plasma glucose in the NGT group were remarkably higher than in the healthy control subjects. Fasting insulin concentrations in the NGT group were also higher than those of the other groups, while postprandial insulin concentrations increased significantly when compared with healthy control subjects. Ferritin concentrations were the highest in type 2 diabetic subjects, followed by the IGT group, the NGT group, and the healthy control group ( $412.88 \pm 155.58$ ,  $354.19 \pm 173.03$ ,  $231.31 \pm 130.32$  [ $P < 0.05$  compared with healthy control subjects], and  $164.69 \pm 110.54$  ng/ml, respectively). In the type 2 diabetic group, the newly diagnosed patients had higher ferritin concentrations than previously diagnosed ( $461.72 \pm 132.41$  vs.  $354.19 \pm 173.03$  ng/ml,  $P < 0.05$ ).

We also compared concentrations of serum ferritin in men and women for each group. In general, concentrations of ferritin in men were higher than in women ( $P < 0.05$ ) except for in the healthy control group. In male subjects, ferritin concentrations of both newly and previously diagnosed type 2 diabetic, IGT, NGT, and healthy control groups showed the same trend as the whole group ( $494.30 \pm 142.6$ ,  $425.01 \pm 136.77$ ,  $390.07 \pm 125.09$ ,  $284.74 \pm 112.04$  [ $P < 0.001$  compared with the healthy control subjects], and  $197.93 \pm 110.41$  ng/ml, respectively). However, in female subjects, ferritin concentrations in newly diagnosed type 2 diabetes and IGT ( $330.72 \pm 131.03$  ng/ml) were higher than the NGT ( $174.06 \pm 123.45$  ng/ml) and healthy control ( $137.28 \pm 89.63$  ng/ml) groups ( $P < 0.001$ ). No significant difference was



found between female NGT and female healthy control subjects. Moreover, in newly diagnosed type 2 diabetes, the concentrations of ferritin were significantly higher than in the previously diagnosed type 2 diabetic and IGT patients.

Using multiple regression analysis, we found an association between ferritin concentration and BMI, waist-to-hip ratio, systolic blood pressure, diastolic blood pressure. HbA<sub>1c</sub>, FPG, 2-h plasma postprandial glucose, triglycerides, and total cholesterol were positively related to ferritin concentrations, while HDL cholesterol levels were inversely related to ferritin concentrations.

In recent years, the issue of the potential pathology of serum ferritin in type 2 diabetes has gained remarkable interest (3). In this study, we found that serum ferritin concentrations were remarkably increased in type 2 diabetes, especially in newly diagnosed patients. Subjects with higher concentrations of ferritin consequently had higher HbA<sub>1c</sub>, glucose, and insulin concentrations. These results further proved a positive association between type 2 diabetes and high plasma ferritin concentrations.

The exact mechanism through which elevated ferritin promotes the development of type 2 diabetes is unknown. Some investigations argued that abnormalities in ferritin metabolism might be a primary cause of type 2 diabetes (4–6). In our study, ferritin concentration in IGT subjects, the high-risk population for type 2 diabetes, already significantly increased when compared with normal control subjects, implying that hyperferritinemia occurs before elevation of plasma glucose concentrations. This observation was further substantiated by evidence that NGT first-degree relatives in the type 2 diabetic pedigrees had higher ferritin concentrations than normal control subjects.

YAN REN, MD, PHD<sup>1</sup>  
 HAOMING TIAN, MD<sup>1</sup>  
 XIUJUN LI, MD<sup>1</sup>  
 JINZHONG LIANG, MD<sup>1</sup>  
 GUIZHI ZHAO,<sup>2</sup>

From the <sup>1</sup>Division of Endocrinology, Department of Internal Medicine, West China Hospital, Sichuan University; and the <sup>2</sup>Laboratory of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China.

Address correspondence to Haoming Tian, MD, Division of Endocrinology, Department of Internal Medicine, West China Hospital of Sichuan Univer-

sity, 37 Guoxue Lane, Chengdu, Sichuan China 610041. E-mail: hmtian999@yahoo.com.cn.

© 2004 by the American Diabetes Association.



References

1. Tuomainen TP, Nyyssonen K, Salonen R, Tervahauta A, Korpela H, Lakka T, Kaplan GA, Salonen JT: Body iron stores are associated with serum insulin and blood glucose concentration: population study in 1,013 eastern Finnish men. *Diabetes Care* 20:426–428, 1997
2. Ford ES, Cogswell ME: Diabetes and serum ferritin concentration among U.S. adults. *Diabetes Care* 22:1978–1983, 1999
3. Salonen JT, Tuomainen TP, Nyyssonen K, Lakka HM, Punnonen K: Relation between iron stores and non-insulin dependent diabetes in men: case-control study (Abstract). *BMJ* 317:727, 1998
4. Moczulski DK, Grzeszczak W, Gawlik B: Role of hemochromatosis C282Y and H63D mutations in HFE gene in development of type 2 diabetes and diabetic nephropathy. *Diabetes Care* 24:1187–1191, 2001
5. Van Lerberghe S, Hermans MP, Dahan K, Buysschaert M: Clinical expression and insulin sensitivity in type 2 diabetic patients with heterozygous for haemochromatosis. *Diabetes Metab* 28:33–38, 2002
6. Salonen JT, Tuomainen TP, Kontula K: Role of C282Y mutation of in haemochromatosis gene in development of type 2 diabetes in healthy men: prospective cohort study. *BMJ* 24:1706–1707, 2000

## Simultaneous Bilateral Facial Palsy in a Diabetic Patient

Unilateral facial paralysis is a relatively common condition with an incidence of 20–25 per 100,000 population. However, simultaneous bilateral facial palsy (facial diplegia) is an extremely rare clinical entity and occurs in 0.3–2% of facial paralysis patients (1). The annual incidence is approximately 1 per 5 million (2).

A 78-year-old diabetic patient presented to the emergency room of our hospital with dysarthry and bilateral symmetrical facial weakness. He was unable to show his teeth, close his eyelids, or dilate his cheeks. From the neurologic examination, there were no other important findings, except for a minor instability during walking. The patient did not refer head injury or febrile viral infection in the recent past. We made the presumptive di-

agnosis of bilateral peripheral facial paralysis. Five weeks after his admission to our hospital, he made a full recovery. We have to note that glucocorticoids were not administered to him.

His full blood count, erythrocyte sedimentation rate, liver function tests, tumor markers, thyroid hormones, serum protein immunoelectrophoresis, serum ACE levels, C-reactive protein, and rapid protein reagent (RPR) were all within normal limits. HbA<sub>1c</sub> was 7.0%, and the autoantibody screen was negative. Purified protein derivative was 5 mm. Serological tests for varied infectious agents, including herpes simplex virus (HSV)-I and -II, Varicella-Zoster virus (VZV), Epstein-Barr, Coxsackie, HIV-I and -II, cytomegalovirus (CMV), and hepatitis B viruses, as well as *Mycoplasma* and *Borrelia Burgdorferi*, were all negative.

Lumbar puncture revealed a normal pressure. Glucose, protein, and white blood count of the cerebrospinal fluid (CSF) were all within normal limits. Furthermore, stains and cultures for microorganisms were negative, as were tests for viruses (HSV and HSV-II, VZV, and CMV), *Borrelia Burgdorferi*, and syphilis (venereal disease reaction level [VDRL] test).

Magnetic resonance imaging (MRI) of the brain and computed tomography (CT) scans of the head, thorax, and abdomen were all normal.

Facial diplegia may have diverse etiologies and may prove to be a diagnostic dilemma. The most common causes are bilateral Bell's palsy, Lyme disease, Guillain-Barre syndrome, sarcoidosis, Moebius syndrome, leukemia, viral infections, syphilis, basilar skull fractures, and pontine gliomas.

The most common infectious cause of facial diplegia is Lyme disease, caused by *Borrelia Burgdorferi* (3). Regarding the case presented, the IgG antibodies against this agent in serum, as well as in CSF, were negative. Other rare infectious causes include syphilis and *Mycoplasma* (4). However, VDRL tests in CSF and RPR in serum were negative, while antibody titer against *Mycoplasma* was negative.

Guillain-Barre syndrome is thought to be a postinfectious inflammatory polyradiculoneuritis. Up to 50% of the fatal cases have bilateral facial paralysis (5). The diagnosis is made on lumbar puncture (with a typically elevated protein in the absence of a raised number of cells)

Downloaded from http://diabetesjournals.org/care/article-pdf/27/2/623/661177628.pdf by guest on 05 October 2022

and peripheral areflexia. Our patient had neither peripheral muscle weakness nor areflexia, and the CSF examination was normal.

Basilar skull fractures and pontine gliomas were excluded by means of both brain CT and MRI. Because there was no hilar adenopathy on chest CT and because serum ACE levels were normal, sarcoidosis was rejected.

Bilateral Bell's palsy does not seem to be a plausible diagnosis because our patient had neither a preceding viral infection nor the characteristic symptoms of this condition (facial numbness or pain, change in taste, numbness of the tongue, hyperacusis, etc.).

Diabetes has previously been associated with facial diplegia (4,6,7). According to Adour, Wingerd, and Doty (7), diabetes was present in 28.4% of 67 patients with recurrent or bilateral facial palsy. A plausible explanation could be that diabetic patients are more prone to nerve degeneration. In another series of 43 patients with bilateral seventh nerve palsy, there was one case associated with diabetes (4). Thus, having excluded all the other possible causes of this disorder after extensive evaluation, we could assume that the most likely cause of facial diplegia in the case presented is diabetes.

In conclusion, bilateral facial paralysis may be due to a life-threatening condition and, therefore, the practitioner should be aware of the diagnostic possibilities that cause this extremely rare condition. A review of the literature reveals that diabetes is associated with facial diplegia and should always be included in the differential diagnosis of this condition.

ALEXANDER KAMARATOS, MD, PHD<sup>1</sup>  
 STELIOS KOKKORIS, MD<sup>1</sup>  
 JOHN PROTOPSALTIS, MD, PHD<sup>1</sup>  
 DIMITRIOS AGORGIANITIS, MD<sup>2</sup>  
 HARIS KOUMPOULIS, MD<sup>2</sup>  
 JOHN LENTZAS, MD<sup>1</sup>  
 ANDREAS MELIDONIS, MD, PHD<sup>3</sup>  
 GREGORY GIANNOULIS, MD, PHD<sup>1</sup>

From the <sup>1</sup>Second Department of Internal Medicine, Tzanio Hospital, Piraeus, Greece; the <sup>2</sup>Neurology Department, Tzanio Hospital, Piraeus, Greece; and the <sup>3</sup>Diabetologic Center, Tzanio Hospital, Piraeus, Greece.

Address correspondence to Alexander Kamaratos, MD, PhD, Tzanio General Hospital of Piraeus, Second Department of Internal Medicine, Tzani and Afentouli 1, Piraeus 185 36, Greece. E-mail: skokkoris2003@yahoo.gr.

© 2004 by the American Diabetes Association.



## References

1. Stahl N, Ferit T: Recurrent bilateral peripheral facial palsy. *J Laryngol Otol* 103: 117–119, 1989
2. George MK, Pahor AL: A cause for bilateral facial palsy. *Ear Nose Throat J* 70: 492–3, 1991
3. Clark JR, Carlson RD, Pachner AR: Facial paralysis in Lyme disease. *Laryngoscope* 95:1341–1345, 1985
4. Keane JR: Bilateral seventh nerve palsy: analysis of 43 cases and review of the literature. *Neurology* 44:1198–1202, 1994
5. Arias G, Nogues J, Manos M, Amilibia E, Dicenta M: Bilateral facial nerve palsy: four case reports. *ORL J Otorhinolaryngol Relat Spec* 60:227–229, 1998
6. Hattori T, Schlagenhauff RE: Bilateral facial palsy: occurrence with diabetes mellitus. *NY State J Med* 77:1492–1494, 1977
7. Adour K, Wingerd J, Doty HE: Prevalence of concurrent diabetes mellitus and idiopathic facial paralysis (Bell's palsy). *Diabetes* 24:449–451, 1975

## Reduced Fear of Hypoglycemia in Successful Islet Transplantation

The recent dramatic improvement in clinical outcomes in islet transplantation in type 1 diabetes with the Edmonton Protocol has led to considerable excitement in the field of diabetes (1,2). The unprecedented 1-year success rates provide considerable evidence of the clinical effectiveness of the procedure (2,3). However, the benefits of freeing or reducing insulin requirements for these patients must be weighed against the risks of the procedure itself, as well as the life-long immunosuppression. Before making this treatment available to a larger number of people with type 1 diabetes, measures of quality of care and of clinical effectiveness must be incorporated to fully evaluate the benefit of this treatment.

Episodes of severe hypoglycemia, a common occurrence in patients with labile type 1 diabetes and hypoglycemia unawareness, result in considerable fear and anxiety (4,5). When these concerns become an overwhelming burden for patients with type 1 diabetes, islet transplantation with the Edmonton Protocol is a potential solution (1–3). To determine the potential impact of islet

transplantation on self-reported health-related quality of life (HRQL) outcomes, we compared islet-transplanted patients with pretransplant patients on measures of fear of hypoglycemia and anxiety.

Patients were asked to self-complete a battery of measures, including the Hypoglycemia Fear Survey (HFS) (4,5) and the Health Utilities Index Mark two (HUI2) (6). The HFS contains 23 questions that assess patients' concerns and worries about hypoglycemia and the behaviors in which patients may engage to avoid low blood glucose. The emotion attribute of the HUI2 can be used as an index of anxiety (6). Our standard protocol for administration of HRQL questionnaires occurs at baseline (pretransplant); midtransplant (i.e., between the first and second); 1, 3, 6, and 12 months posttransplant; and annually thereafter. Because islet-transplanted patients may have completed multiple surveys during follow-up, we initially used only the last available HRQL assessment. Surveys were completed by 81 (46 pretransplant and 35 islet-transplanted) patients. Among the islet-transplanted patients, questionnaires were completed a median of 11.9 months (range 1–36) after transplant. Scores between the two groups of patients were compared using nonparametric statistical tests.

Fear of hypoglycemia was significantly lower in islet-transplanted (median 5.0) compared with pretransplant (median 47.0) patients for the HFS total score ( $P < 0.001$ ). The magnitude of the difference in HUI2 emotion scores between pretransplant and islet-transplanted patients would be considered clinically important (6) (1.00 vs. 0.86, respectively), although the difference was not statically significant ( $P = 0.96$ ). Among all islet-transplanted patients, the small number ( $n = 3$ ) without C-peptide secretion and requiring exogenous insulin had substantially more fear about hypoglycemia ( $P = 0.041$ ) and reported more anxiety on the HUI2 emotion attribute ( $P = 0.023$ ) than islet-transplanted patients with successful transplants.

Because anxiety pre- and posttransplant could be related to the procedure itself, we also compared HFS and HUI2 emotion scores between pretransplant and islet-transplanted patients in the immediate posttransplant period; for these comparisons, we used all available HRQL assessments at 1 and 3 months posttransplant. We found that fear of hypoglyce-

mia was lower, with a median HFS total of 30.0 for islet-transplanted patients ( $n = 20$ ) at 1 month and 6.5 ( $n = 18$ ) at 3 months, both of which were significantly lower ( $P < 0.01$ ) than pretransplant. Conversely, the HUI2 emotion score was not significantly different from pretransplant at either 1 or 3 months posttransplant.

These initial evaluations of self-reported HRQL outcomes of in islet transplant recipients demonstrate that clinical success is associated with substantial reduction in emotional burden through reduced fear of hypoglycemia. General anxiety in islet-transplanted patients is reduced overall, which seems to be related to the freedom from requirement of exogenous insulin rather than to recovering from the transplant procedure itself. Although the interpretation of our initial data is interesting and informative, several limitations and questions remain. These initial data were collected cross-sectionally and on a relatively small but growing sample of islet-transplanted patients; even with the small sample sizes, the observed differences were statistically significant. Longitudinal assessments to measure within-person change over time are required to fully assess the impact on HRQL.

JEFFREY A. JOHNSON, PHD<sup>1,2</sup>

MARIA KOTOVYCH, MA<sup>2</sup>

EDMOND A. RYAN, MD, FRCPC<sup>3,4</sup>

A.M. JAMES SHAPIRO, MBBS, BMEDSCI,  
PHD, FRCSC<sup>4,5</sup>

From the <sup>1</sup>Department of Public Health Sciences, University of Alberta, Edmonton, Alberta, Canada; the <sup>2</sup>Institute of Health Economics, Edmonton, Alberta, Canada; the <sup>3</sup>Division of Endocrinology and Metabolism, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada; the <sup>4</sup>Clinical Islet Transplant Program, University of Alberta, Edmonton, Alberta, Canada; and the <sup>5</sup>Department of Surgery, University of Alberta, Edmonton, Alberta, Canada.

Address correspondence to Jeffrey A. Johnson, PhD, Institute of Health Economics, 1200-10405 Jasper Ave., Edmonton, Alberta, Canada T5J 3N4. E-mail: jeff.johnson@ualberta.ca.

© 2004 by the American Diabetes Association.

## References

1. Shapiro AMJ, Lakey JRT, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV: Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. *N Engl J Med* 343:

230–238, 2000

2. Ryan EA, Lakey JR, Rajotte RV, Korbutt GS, Kin T, Imes S, Rabinovitch A, Elliott JF, Bigam D, Kneteman NM, Warnock GL, Larsen I, Shapiro AM: Clinical outcomes and insulin secretion after islet transplantation with the Edmonton Protocol. *Diabetes* 50:710–719, 2001
3. Ryan EA, Lakey JRT, Paty BW, Imes S, Korbutt GS, Kneteman NM, Bigam D, Rajotte EV, Shapiro AMJ: Successful islet transplantation: continued insulin reserve provides long-term glycemic control. *Diabetes* 51:2148–2157, 2002
4. Cox D, Irvine A, Gonder-Frederick L, Nowacek G, Butterfield J: Fear of hypoglycemia: quantification, validation, and utilization. *Diabetes Care* 10:617–621, 1987
5. Irvine A, Cox D, Gonder-Frederick L: The fear of hypoglycemia scale. In *Handbook of Psychology and Diabetes*. Bradley C, Ed. Amsterdam, Hardwood Academic, 1994, p. 133–155
6. Feeny DH, Torrance GW, Furlong WJ: Health utilities index. In *Quality of Life and Pharmacoeconomics in Clinical Trials*. 2nd ed. Spilker B, Ed. Philadelphia, Lippincott-Raven, 1996, p. 239–251

## A Case of Lipoatrophy With Lispro Insulin Without Insulin Pump Therapy

**L**ocalized lipoatrophy occurring in the subcutaneous insulin injection area in diabetic patients was a phenomenon practically forgotten after the introduction of human insulin in medical practice. In recent years, there have been very few publications in relation to this matter.

Three cases of patients with type 1 diabetes who presented with subcutaneous localized lipoatrophy areas and who were in treatment with Lispro insulin were recently reported (1,2). The three patients used a continuous subcutaneous insulin infusion (CSII) system; therefore, the authors posed the doubt of whether such an administration system locally played a determinant role in the occurrence of subcutaneous localized lipoatrophy.

We present a case of localized lipoatrophy associated with treatment with

Lispro insulin administered in a multiple dose regimen that disregards the role of CSII as a necessary factor for its genesis.

Our patient is a 35-year-old woman diagnosed in January of 1992 at 22 years of age. From the start, she was treated with recombinant DNA human insulin (Humulin Regular and Humulin NPH; Lilly) in a regimen of three daily doses. She always exhibited a good degree of metabolic control, with HbA<sub>1c</sub> between 6 and 7%. Seven years after diagnosis, she began to exhibit episodes of hypoglycemia not perceived with accompanying neuroglycopenia, which persisted in spite of several changes of her prior insulin regimen. For that reason, in November of 2000 it was decided that she would change to LisPro insulin administered before breakfast, lunch, snack, and dinner, and NPH insulin administered before breakfast and dinner. With the new regimen, metabolic control remained similar to the previous control and the episodes of neuroglycopenia persisted. Anti-insulin antibody (IAA) levels were measured and were high (49.6%, reference value <8.5%). In October of 2002, 23 months after beginning with LisPro, the patient consulted the physician because she had a circumscribed localized lipoatrophy area of ~3 cm in diameter on the anterior aspect of the right thigh, one of her normal injection areas. Six months later, a period in which injection in said area was avoided, the lesion remained unchanged, but an incipient localized lipoatrophy area could be observed in the same area of the contralateral thigh. For this reason, it was decided to change from Lispro to Aspart insulin.

Six months after said change of insulin, which was when this letter was sent, neither progression nor improvement of the localized lipoatrophy lesions had been observed. IAA levels were 30.5%, slightly lower than the previous levels.

The development of localized lipoatrophy in the insulin injection area is a practically exclusive complication of type 1 diabetic patients, although cases have been reported in patients with type 2 diabetes (3). From the etiopathogenic point of view, it is considered an immunological phenomenon. Although this has not been sufficiently clarified, a strong association between the lesions and high IAA plasma levels and the presence of insulin and immunoglobulin G deposits in subcutaneous tissue of the affected areas (4) have

been reported. The consequences of this immunological activation are the local inhibition of adipocyte differentiation, probably mediated by the local hyperproduction of tumor necrosis factor- $\alpha$  (5).

In affected patients, the pharmacokinetic variations of insulin due to high IAA levels and the erratic absorption of the drug when it is injected in the areas affected with localized lipotrophy imply a glycemic variability making it very difficult to achieve suitable metabolic control.

Although the immunogenic profile of the patients treated with Lispro insulin and recombinant human insulin are comparable (6), the recent occurrence of descriptions of localized lipotrophy associated to this analogue can decrease the therapeutic alternatives of this complication when, especially in recent years, in the few published cases of human insulin-induced localized lipotrophy the attempted solution to the problem was to change to Lispro. It is possible that the use of CSII may favor the occurrence of localized lipotrophy but, as can be seen in the case we present, it is not a factor *sine qua non* for its development. Curiously, severe cases of human insulin-induced localized lipotrophy have been previously reported that responded satisfactorily after the introduction of CSII (7).

The association of localized lipotrophy and Lispro insulin without the course of CSII has not been reported previously. We therefore believe it is interesting to disclose our case and to encourage publishing for other diabetologists who have observed similar cases for the purpose of clarifying its pathogenesis and therapeutic approach.

ALFONSO ARRANZ, MD  
VICTOR ANDÍA, MD  
ANTONIO LÓPEZ-GUZMÁN, MD

From the Endocrinology Unit, Hospital Nuestra Señora de Sonsoles, Avila, Spain.

Address correspondence to Dr. Alfonso Arranz, Endocrinology Unit, Ntra. Sra. De Sonsoles, Carretera de Madrid, km 109, Avila, Spain 05071. E-mail: aarranz@hnss.sacyl.es.

© 2004 by the American Diabetes Association.

## References

1. Griffin ME, Feder A, Tamborlane WV: Lipotrophy associated with lispro insulin in insulin pump therapy (Letter). *Diabetes Care* 24:174, 2001
2. Ampudia-Blasco FJ, Hasbun B, Carmena R: A new case of lipotrophy with lispro

insulin in insulin pump therapy (Letter). *Diabetes Care* 26:953–954, 2003

3. Mu L, Goldman JM: Human recombinant DNA insulin-induced lipotrophy in patient with type 2 diabetes mellitus. *Endocr Pract* 6:151–152, 2000
4. Reeves WG, Allen BR, Tattersall RB: Insulin induced lipotrophy evidence for an immune pathogenesis. *BMJ* 1:1500–1506, 1980
5. Atlan-Gepner C, Bondgrand P, Farnarier C, Xerri L, Choux R, Gauthier JF, Brue T, Vague P, Grob JJ, Vialettes B: Insulin-induced lipotrophy in type 1 diabetes: a possible tumor necrosis factor- $\alpha$ -mediated dedifferentiation of adipocytes. *Diabetes Care* 19:1283–1285, 1996
6. Fineberg SE, Huang J, Brunelle R, Gulliya KS, Anderson JH: Effect of long-term exposure to insulin Lispro on the induction of antibody response in patients with type 1 or type 2 diabetes. *Diabetes Care* 26:89–96, 2003
7. Chantelau E, Reuter M, Schotes S, Starke AA: Severe lipotrophy with human insulin: successfully treated by CSII (Letter). *Diabet Med* 10:580–581, 1993

## Diabetes In A Nonpancreatectomized Child With Nesidioblastosis

Persistent hyperinsulinemic hypoglycemia of infancy (PHHI) (Online Mendelian Inheritance in Man [OMIM] 256450), formerly known as nesidioblastosis, is a glucose metabolism disorder characterized by profound hypoglycemia and inappropriate secretion of insulin (1). Affected children run the risk of severe neurological damage unless immediate and adequate steps are taken (2). Treatment with diazoxide and/or somatostatin analogue is the first line of therapy. However, it not always effective, especially in familial cases, which may necessitate an alternative intervention such as pancreatectomy (3).

Several studies have suggested that partial pancreatectomy endangers future islet cell function (4,5). The incidence of diabetes increases with age and correlates with the extent of surgical resection (6,7). However, there was no report of occurrence of overt diabetes in medically treated patients (8). In this report, we de-

scribed an adolescent female with neonatal nesidioblastosis who developed diabetes after medical treatment with diazoxide/octreotide. To our knowledge, this is the first nesidioblastosis case subject who developed diabetes following medical therapy.

A 14-year-old Saudi female presented with severe persistent hypoglycemia during the first few days of life. She was diagnosed with hyperinsulinemic hypoglycemia of infancy based on her intravenous glucose requirement of  $>14 \text{ mg} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$ , an insulin-to-glucose ratio of  $>0.3$  (her insulin level was  $98 \mu\text{U/ml}$  at a serum glucose of  $32 \text{ mg/dl}$ ), negative urinary ketones, a 30-min glucose increment of  $\geq 30 \text{ mg/dl}$  in response to intramuscular  $0.5 \text{ mg}$  glucagon, and normal blood spot acylcarnitine profile determined by tandem mass spectrometry. She also had a normal growth hormone level of  $>20 \text{ mU/l}$  and a normal cortisol level of  $>500 \text{ nmol/l}$  during hypoglycemia. She was treated initially with frequent feeding supplemented with complex carbohydrates (polycose/corn starch) and then started on diazoxide  $15 \text{ mg} \cdot \text{kg}^{-1} \cdot \text{day}^{-1}$  divided three times a day, which kept her euglycemic with occasional hypoglycemic episodes. In 1992, octreotide was first introduced in our hospital as an adjunctive therapy to diazoxide. She was started on  $25 \mu\text{g} \cdot \text{kg}^{-1} \cdot \text{day}^{-1}$  of subcutaneous octreotide divided four times a day. She responded to medical treatment with no hypoglycemic episodes. She was continued on diazoxide and octreotide until the age of 10 years, when she became euglycemic and these two medications were stopped. At the age of 14, she developed hyperglycemia associated with weight gain. Her blood glucose ranged from 200 to 300 mg/dl, and her weight was 75 kg ( $>95\%$ ). She had an insulin level of  $10 \mu\text{U/ml}$  and C-peptide level of  $0.16 \text{ nmol/l}$  at a serum glucose level of 350 mg/dl. Antigliutamic acid decarboxylase, insulin, and islet cell antibodies were negative. She responded to metformin 250 mg twice a day with a serum mean glucose level of 109 mg/dl and HbA<sub>1c</sub> of 7.5%.

The long-term outcome of PHHI is not well documented. Previous reports suggested that subtotal or near total pancreatectomy in infants will endanger the future islet function (4–8). Long-term follow-up studies in medically treated patients with diazoxide or octreotide showed that some of these patients re-

sponded to medical therapy and became euglycemic (9–11). Some patients were weaned off medical therapy and continued to be euglycemic; however, none of them became hyperglycemic or diabetic. Leibowitz et al. (8) followed six conservatively treated patients with PPHI. Intravenous glucose tolerance was performed in all patients and showed a blunted insulin response in two with no overt hyperglycemia. Histologically, Kassem et al. (12) showed that  $\beta$ -cell proliferation and apoptosis, which normally occurs in the normal developing human pancreas, also occurs in the PPHI pancreas with a higher frequency of apoptosis. They suggested that this phenomenon will result in a slow, progressive, and complete loss of  $\beta$ -cell mass. This histological report and the development of diabetes in our non-pancreatectomized PPHI patient may suggest that patients with PPHI will naturally develop diabetes whether they were treated medically or surgically or even if they are left untreated. This hypothesis was further raised when the natural history of this disease was discussed in knockout mouse models. Transgenic mice engineered to express a dominant-negative form of Kir6.2 or mice with ATP-sensitive  $K^+$  channel deficiency developed hyperinsulinemic hypoglycemia followed by hypoinsulinemic hyperglycemia. Diabetes in these transgenic mice was thought to be due to sustained unregulated Ca influx and premature  $\beta$ -cell apoptosis (burn-out phenomenon) (13,14). Seino et al. (15,16) reported another possible predisposing factor to hyperglycemia in PPHI patients. They showed that hyperglycemia in Kir6.2 knockout mice was more evident with age and increasing weight. They suggested that the Kir6.2 knockout mouse provides a model of type 2 diabetes, and that both the genetic defect in glucose-induced insulin secretion and the acquired insulin resistance due to environmental factors are necessary to develop diabetes in the Kir6.2 knockout mouse.

We hypothesized that diabetes was induced by weight gain and obesity in our patient. She responded to metformin, which may suggest that her diabetes is due to insulin resistance induced by both weight gain and insulin insufficiency. Simple type 2 diabetes is still a possibility, although there was no history of diabetes in the family. This patient could be the human example of the Kir6.2 knockout

mouse model. We recommend, based on this human clinical evidence, weight control in aged PPHI patients to decrease the incidence of diabetes.

BASSAM S. BIN-ABBAS, MD  
 ABDULLAH A. AL-ASHWAL, MD

From the Department of Pediatrics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Address correspondence to Bassam Saleh Bin-Abbas, MD Consultant, Section of Pediatric Endocrinology Department of Pediatrics, MBC 58 King Faisal Specialist Hospital and Research Center, P.O. Box 3354 Riyadh 11211 Saudi Arabia. E-mail: benabbas@kfshrc.edu.sa.

© 2004 by the American Diabetes Association.



References

1. Aynsley-Green A: Nesidioblastosis of the pancreas in infancy. *Dev Med Child Neurol* 23:372–379, 1981
2. Schwitzgebel VM, Gitelman SE: Neonatal hyperinsulinism. *Clin Perinatol* 25:1015–1038, 1998
3. Shilyansky J, Fisher S, Cutz E, Perlman K, Filler RM: Is 95% pancreatectomy the procedure of choice for the treatment of persistent hyperinsulinemic hypoglycemia of the neonate? *J Pediatr Surg* 32:342–346, 1997
4. Dunger DB, Burns C, Ghale GK, Muller DP, Spitz L, Grant DB: Pancreatic exocrine and endocrine function after subtotal pancreatectomy for nesidioblastosis. *J Pediatr Surg* 23:112–115, 1988
5. Mahachoklertwattana P, Suprasongsin C, Teeraratkul S, Preeyasombat C: Persistent hyperinsulinemic hypoglycemia of infancy: long-term outcome following subtotal pancreatectomy. *J Pediatr Endocrinol Metabol* 13:37–44, 2000
6. De Lonlay-Debeney P, Poggi-Travert F, Fournet JC, Sempoux C, Vici CD, Brunelle F, Touati G, Rahier J, Junien C, Nihoul-Fekete C, Robert JJ, Saudubray JM: Clinical features of 52 neonates with hyperinsulinism. *N Engl J Med* 340:1169–1175, 1999
7. Dacou-Voutetakis C, Psychou F, Maniati-Christidis M: Persistent hyperinsulinemic hypoglycemia of infancy: long term results. *J Pediatr Endocrinol Metabol* 11:131–141, 1998
8. Leibowitz G, Glaser B, Higazi AA, Salameh M, Cerasi E, Landau H: Hyperinsulinemic hypoglycemia of infancy (nesidioblastosis) in clinical remission: high incidence of diabetes mellitus and persistent beta-cell dysfunction at long term follow-up. *J Endocrinol Metabol* 80:386–392, 1995
9. Tuoti G, Poggi-Travert F, Ogier de Baulny H, Rahier J, Brunelle F, Nihoul-

- Fekete C, Czernichow P, Saudubray JM: Long-term treatment of persistent hyperinsulinemic hypoglycemia of infancy with diazoxide: a retrospective review of 77 cases and analysis of efficacy-predicting criteria. *Eur J Pediatr* 157:628–633, 1998
10. Glaser B, Landau H: Long-term treatment with somatostatin analogue SMS 201–995: alternative to pancreatectomy in persistent hyperinsulinemic hypoglycemia of infancy. *Digestion* 45:27–35, 1990
11. Darendeliler F, Bundak R, Bas F, Saka N, Gunoz H: Long term diazoxide treatment in persistent hyperinsulinemic hypoglycemia of infancy: a patient report. *J Pediatr Endocrinol Metabol* 10:79–81, 1997
12. Kassem SA, Ariel I, Thornton PS, Scheimberg I, Glaser B:  $\beta$ -Cell proliferation and apoptosis in the developing normal human pancreas and in the hyperinsulinism of infancy. *Diabetes* 49:1325–1333, 2000
13. Miki T, Tashiro F, Iwanaga T, Nagashima K, Yoshitomi H, Aihara H, Nitta Y, Gono T, Inagaki N, Miyazaki JI, Seino S: Abnormalities of pancreatic islets by targeted expression of a dominant-negative KATP channel. *Proc Natl Acad Sci U S A* 94:11969–11973, 1997
14. Miki T, Nagashima K, Tashiro F, Kotake K, Yoshitomi H, Tamamoto A, Gono T, Iwanaga T, Miyazaki JI, Seino S: Defect in insulin secretion and enhanced insulin action in KATP deficient mice. *Proc Natl Acad Sci U S A* 95:10402–10406, 1998
15. Seino S, Iwanaga T, Nagashima K, Miki T: Diverse roles of  $K_{ATP}$  channels learned from Kir6.2 genetically engineered mice. *Diabetes* 49:311–318, 2000
16. Winarto A, Miki T, Seino S, Iwanaga T: Morphological changes in pancreatic islets of KATP channel-deficient mice: the involvement of KATP channels in the survival of insulin cells and the maintenance of islet architecture. *Arch Histol Cytol* 64:59–67, 2001

## Oral Glucose Tolerance Test Evaluation With Forearm and Fingertip Glucose Measurements in Pregnant Women

It is known that glucose levels in capillary blood in the fingertip after a liquid glucose load are constantly higher when compared with venous blood measurements (1). Recently alternative sites

Downloaded from http://diabetesjournals.org/care/article-pdf/27/2/627/661177628.pdf by guest on 05 October 2022

for capillary blood drawing (e.g., forearm) have been proposed (2) that are less painful compared with fingertip. Data have shown that there was no significant difference between the capillary blood drawn from forearm and fingertip in diabetic patients with glucose values in a wide range (3). Nevertheless, some data have shown that glucose results from alternative sites and fingertip were not identical. This difference was more pronounced when there was a rapid increase or decrease of blood glucose values (4). It seemed that significant differences appeared when glucose values declined at a mean rate  $>2 \text{ mg} \cdot \text{dl}^{-1} \cdot \text{min}^{-1}$  (5), but not at a lower rate (6). All the above-mentioned reports compared capillary blood drawn from either the forearm or fingertip, but so far, it appears that no direct comparison has been made between venous plasma blood and capillary forearm blood.

Thus, the purpose of this investigation is to study the pattern of capillary forearm blood and that of capillary fingertip blood glucose using the same glucometer (FreeStyle; Therasense) and to compare both with venous blood laboratory measurements during a 100-g oral glucose tolerance test (OGTT) in pregnant women. A total of 47 pregnant women (age  $31 \pm 3$  years, BMI  $24 \pm 3 \text{ kg/m}^2$ , and gestational age 24–28 weeks) underwent a 100-g OGTT. Half of these women ( $n = 23$ ) had simultaneous glucose samples drawn from the forearm after rubbing (7) using FreeStyle in 0', 60', 120', and 180', whereas the other half ( $n = 24$ ) underwent the same procedure with blood drawn from the fingertip. The two groups were matched for age, BMI, and gestational age. Glucose difference in percentage (GDP) was calculated for both groups separately. Mean GDP between finger glucose and venous glucose samples was significantly higher at 60' ( $14.6 \pm 20.4\%$ ), 120' ( $25.2 \pm 34.7\%$ ), and 180' ( $26.4 \pm 26.7\%$ ) than at 0' ( $-3.1 \pm 14.1\%$ ) ( $P < 0.01$ ). Mean GDP between forearm glucose and venous glucose samples was significantly higher at 120' ( $16.3 \pm 21.5\%$ ) and 180' ( $16.3 \pm 21.5\%$ ) than at 0' ( $-2.5 \pm 16.3\%$ ) ( $P < 0.01$ ). On the contrary, mean GDP at 60' ( $6.7 \pm 20.9\%$ ) was not found significantly different.

These findings confirmed the already reported observation that up to 3 h after a liquid glucose load, capillary finger glu-

cose levels are constantly higher (15–26%) than venous glucose levels. On the contrary, forearm glucose levels were closer to venous plasma glucose levels: There was no significant difference between them after 1 h, whereas a significant increase of 16% appeared at 2 and 3 h. These findings are in accordance with the concept of slower glucose kinetics at the forearm than the fingertip due to lesser arteriovenous anastomoses (4). To be sure, this physiological difference needs to be taken into consideration in the detection of hypoglycemia in diabetic patients. However, it is precisely this physiological difference that supports the suggestion that capillary forearm glucose measurements using a portable glucose meter may be useful for the 50-g challenge test for gestational diabetes screening in an outpatient environment.

CHARALAMPOS STAVRIANOS, MD  
ELENI ANASTASIOU, MD

From the First Endocrine Section, Diabetes Center, Alexandra Hospital, Athens, Greece.

Address correspondence to Eleni Anastasiou, MD, Alexandra Hospital, First Endocrine Section, Diabetes Center, 80 V. Sofias Ave., Athens 11528, Greece. E-mail: mileleni@hol.gr.

© 2004 by the American Diabetes Association.



#### References

1. Kuwa K, Nakayama T, Hoshino T, Tomimaga M: Relationships of glucose concentrations in capillary whole blood, venous whole blood and venous plasma. *Clin Chim Acta* 307:187–192, 2001
2. Ellison JM, Stegmann JM, Colner SL, Michael RH, Sharma MK, Ervin KR, Horwitz DL: Rapid changes in postprandial blood glucose produce concentration differences at finger, forearm, and thigh sampling sites. *Diabetes Care* 25:961–964, 2002
3. Lock JP, Szuts EZ, Malomo KJ, Anagnostopoulos A: Whole-blood glucose testing at alternate sites: glucose values and hematocrit of capillary blood drawn from fingertip and forearm. *Diabetes Care* 25:337–341, 2002
4. Jungheim K, Koschinsky T: Glucose monitoring at the arm: risky delays of hypoglycemia and hyperglycemia detection. *Diabetes Care* 25:956–960, 2002
5. Jungheim K, Koschinsky T: Response to the letter by Pfützner and Forst (Letter). *Diabetes Care* 25:639–640, 2002
6. Pfützner A, Forst T: Response to Jungheim and Koschinsky (Letter). *Diabetes Care* 25:638–639, 2002
7. McGarraugh G: Response to Jungheim

and Koschinsky: glucose monitoring at the arm (Letter). *Diabetes Care* 24:1304–1306, 2001

## Silent Hypoglycemia Presenting As Dysesthesias

Hypoglycemia is not often in the differential diagnosis for dysesthesias but should be considered when involved in the care of diabetic patients. Such symptoms may herald silent hypoglycemia and resultant nerve injury, as illustrated in the following case.

A 26-year-old female with type 1 diabetes presented with a 2-month history of numbness and tingling in her hands and feet upon waking in the morning. Symptoms began when her treatment was altered from NPH 50 units q A.M. to NPH 35 and Regular 3 q A.M. and NPH 8 and Regular 5 at dinner. The patient monitored her glucose more than four times each day and reported three to four glucose values a week that were  $<60 \text{ mg/dl}$  without symptoms. Her morning glucose levels averaged 60 mg/dl. The symptoms were more pronounced in her hands than feet and resolved within minutes. On exam, she showed no objective sensory loss, possessed good muscle tone, bulk, and strength, had intact reflexes (2+) bilaterally, and had no focal neurological signs. HbA<sub>1c</sub> was 6.8%.

Symptoms were attributed to peripheral neuropathy secondary to hypoglycemia. Her insulin regimen was adjusted to NPH 35 and Regular 3 q A.M., NPH 4 q HS, and Regular 5 before dinner for glucose  $>200 \text{ mg/dl}$ . One month later, she reported the disappearance of the symptoms and a reduction in the frequency of values  $<60 \text{ mg/dl}$  to once a week.

Hypoglycemia has been proposed to induce nerve injury by several mechanisms. Lack of substrate leads to a reduction in axonal transport, causing an accumulation of intraneural metabolites and neuronal injury (1). Hypoglycemia can induce a reduction in blood flow, leading to neural hypoxia (2–4). These mechanisms may all play a role in nerve injury; disturbance in neural blood flow may be the initial manifestation of hypo-

glycemia, while prolonged hypoglycemia may induce axonal damage (2).

Peripheral neural injury has been reported in patients with hypoglycemia due to insulinomas (5). These patients displayed paresthesias and/or muscle wasting and weakness. After tumor resection, patients showed resolution of sensory symptoms, while muscle wasting persisted.

We propose that practitioners consider undetected hypoglycemia as a possible cause of paresthesias in diabetic subjects. Frequent episodes of hypoglycemia can hinder patients' efforts to achieve normoglycemia. Early measures taken to reduce such episodes will promote normoglycemia.

NOLAWIT TESFAYE, BS  
ELIZABETH R. SEAQUIST, MD

From the Division of Endocrinology and Diabetes, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota.

Address correspondence to Elizabeth R. Seaquist, MD, MMC 101, 420 Delaware St. SE, University of Minnesota, Minneapolis, MN 55455. E-mail: seaqu001@umn.edu.

© 2004 by the American Diabetes Association.

## References

1. Sidenius P, Jakobsen J: Anterograde fast component of axonal transport during insulin-induced hypoglycemia in nondiabetic and diabetic rats. *Diabetes* 36:853–858, 1987
2. Ohshima J, Nukada H: Hypoglycaemic neuropathy: microvascular changes due to recurrent hypoglycaemic episodes in rat sciatic nerve. *Brain Res* 947:84–89, 2002
3. Kihara M, Zollman PJ, Smithson IL, Lagerlund TD, Low PA: Hypoxic effect of exogenous insulin on normal and diabetic peripheral nerve. *Am J Physiol* 266:E980–E985, 1994
4. Hilsted J, Bonde-Petersen F, Norgaard MB, Greniman M, Christensen NJ, Parving HH, Suzuki M: Haemodynamic changes in insulin-induced hypoglycaemia in normal man. *Diabetologia* 26:328–332, 1984
5. Jaspan JB, Wollman RL, Bernstein L, Rubenstein AH: Hypoglycemic peripheral neuropathy in association with insulinoma: implication of glucopenia rather than hyperinsulinism. *Medicine* 61:33–44, 1982

## Exercise Increases Adiponectin Levels and Insulin Sensitivity in Humans

Adiponectin is an abundant circulating adipocytokine with anti-inflammatory properties (1) linked to cardiovascular disease, type 2 diabetes, and obesity (2–5). Numerous reports (3–5), including the present one, confirm plasma adiponectin levels to be inversely related to insulin resistance. Longer term, a rise in adiponectin has been shown to occur in response to weight loss and glitazone therapy, but not after chronic exercise training. However, understanding of the shorter-term regulation of adiponectin in particular remains unclear. As an extension to a previously reported exercise intervention in sedentary males by our group (6), we have now examined the effects of this training intervention on adiponectin levels in overweight males. We demonstrate that the short-term exercise training increased circulating adiponectin levels with accompanied improved insulin sensitivity.

Twenty-six overweight males participated in an exercise program, as previously described (6). Full data were available on 19 subjects who completed the entire program. At baseline and post-exercise intervention, all subjects were assessed for anthropometric measures (dual-energy X-ray absorptiometry, magnetic resonance imaging, and BMI), insulin sensitivity (insulin clamp), and indirect calorimetry (for fat oxidation rates), and overnight fasting plasma samples were collected for adiponectin levels. Briefly, exercise consisted of aerobic exercise (brisk walking mixed with light jogging) 4–5 days per week for 40 min per session (~55–70%  $\dot{V}O_{2\max}$ ) over 10 weeks (6). Plasma adiponectin was determined using a radioimmunoassay kit (Linco Research, St. Charles, MO). Two-tailed paired Student's *t* tests were used for comparisons between time points before and after exercise, and associations between continuous variables were investigated using simple regression analyses. Analyses were performed using StatView software (version 4.5; Abacus Concepts, Berkeley, CA).

The subjects' mean age was  $37.1 \pm 1.3$  years, and before exercise mean BMI was  $30.7 \pm 0.7$  kg/m<sup>2</sup> and  $\dot{V}O_{2\max}$  was  $48.4 \pm 0.8$  ml · kg fat-free mass (FFM)<sup>-1</sup> · min<sup>-1</sup>. Correlations between glucose infusion rate (GIR), a measure of insulin sensitivity, and indexes of adiposity in the sedentary males were highly significant (all  $P < 0.0001$ ). Fasting plasma adiponectin levels were strongly inversely related to insulin resistance in these subjects ( $r = -0.52$ ,  $P = 0.0007$ ) and to total fat ( $r = -0.39$ ,  $P = 0.015$ ), central subcutaneous fat ( $r = -0.37$ ,  $P = 0.02$ ), and visceral fat mass ( $r = -0.32$ ,  $P = 0.05$ ). Two to three bouts of moderately intense aerobic exercise performed within ~1 week of baseline assessments resulted in a mean 23% increase in GIR ( $35.0 \pm 2.7$  vs.  $43.0 \pm 2.8$   $\mu\text{mol} \cdot \text{min}^{-1} \cdot \text{kg FFM}^{-1}$ ,  $P < 0.0001$ ) and a mean 37% increase in basal fat oxidation rate ( $1.05 \pm 0.14$  vs.  $1.44 \pm 0.08$  g · day<sup>-1</sup> · kg FFM<sup>-1</sup>). These effects were maintained after 10 weeks of exercise training ( $42.4 \pm 3.1$   $\mu\text{mol} \cdot \text{min}^{-1} \cdot \text{kg FFM}^{-1}$  and  $1.35 \pm 0.07$  g · day<sup>-1</sup> · kg FFM<sup>-1</sup>, respectively). Body weight was unchanged after two to three bouts of exercise ( $93.5 \pm 1.9$  vs. baseline  $93.4 \pm 1.8$  kg) and was not significantly reduced at 10 weeks ( $92.6 \pm 1.9$  kg,  $P = 0.08$ ) in this cohort.

Adiponectin levels rose by 260% after two to three bouts of exercise (~1 week) ( $7.0 \pm 0.7$  vs.  $18.2 \pm 1.9$   $\mu\text{g/ml}$ ,  $P < 0.0001$ ) despite unchanged body weight and remained elevated ( $16.4 \pm 1.9$   $\mu\text{g/ml}$ ,  $P < 0.0001$ ) after 10 weeks. However, individual changes in adiponectin levels after two to three bouts (~1 week) and after 10 weeks of exercise were not correlated with the respective changes in insulin sensitivity or fat oxidation rate. Our results contrast with Hulver et al. (7) where adiponectin is unaltered with exercise training despite enhanced insulin action. However, we assessed the acute effect of exercise after two to three bouts of exercise (6), whereas they took their "basal" samples 6 weeks after a ramping exercise period before the 6-month endurance exercise training program (7). Our data indicate that elevated adiponectin levels are first apparent after 1 week (two to three bouts) of moderately intense exercise. We suggest that it is likely that this short-term moderate exercise training can modify regulation of adiponectin, and this could be postulated to provide another mechanism by which exercise re-

duces atherogenic risk, at least in overweight males.

**Acknowledgments**—We acknowledge the assistance of the nursing staff of the Clinical Research Facility, laboratory technicians of the Diabetes Research Group, Dr. Judith Freund and technicians of the Nuclear Medicine Department, St Vincent's Hospital Sydney, and volunteers who participated in this study.

ADAMANDIA D. KRIKETOS, PHD  
SENG KHEE GAN, MBBS, FRACP  
ANN M. POYNTEN, MBBS, FRACP  
STUART M. FURLER, PHD  
DONALD J. CHISHOLM, MBBS, FRACP  
LESLEY V. CAMPBELL, MBBS, FRACP

From the Diabetes and Obesity Research Program, Garvan Institute of Medical Research, Sydney, Australia.

Address correspondence to Dr. Adamandia D. Kriketos, Diabetes and Obesity Research Program, Garvan Institute of Medical Research, 384 Victoria St., Sydney, NSW 2010, Australia. E-mail: a.kriketos@garvan.org.au.

© 2004 by the American Diabetes Association.

## References

- Okamoto Y, Arita Y, Nishida M, Muraguchi M, Ouchi N, Takahashi M, Igura T, Inui Y, Kihara S, Nakamura T, Yamashita S, Miyagawa J, Funahashi T, Matsuzawa Y: An adipocyte-derived protein, adiponectin, adheres to injured vascular walls. *Horm Metab Res* 32:47–50, 2001
- Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. *Biochem Biophys Res Commun* 257:79–83, 1999
- Hotta K, Funahashi T, Arita Y, Takahashi M, Motosuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. *Arterioscler Thromb Vasc Biol* 20:1595–1599, 2000
- Hotta K, Funahashi T, Bodkin NL, Ortmeier HK, Arita Y, Hansen BC, Matsuzawa Y: Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. *Diabetes* 50: 1126–1133, 2001
- Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. *J Endocrinol Metab* 86:1930–1935, 2001
- Gan SK, Kriketos AD, Ellis BA, Thompson CH, Kraegen EW, Chisholm DJ: Changes in aerobic capacity and visceral fat but not myocyte lipid levels predict increased insulin action after exercise in overweight and obese men. *Diabetes Care* 26:1706–1713, 2003
- Hulver MW, Zheng D, Tanner CJ, Houmard JA, Kraus WE, Slentz CA, Sinha MK, Pories WJ, MacDonald KG, Dohm GL: Adiponectin is not altered with exercise training despite enhanced insulin action. *Am J Physiol* 283:E861–E865, 2002

## High Glucose Levels Induce an Increase in Membrane Antioxidants, in Terms of Vitamin E and Coenzyme Q10, in Children and Adolescents With Type 1 Diabetes

Oxidative stress is defined as an imbalance between prooxidants and antioxidants in favor of the former (1), and diabetic patients are considered a risk group for increased oxidative stress (2,3). Studies regarding oxidant/antioxidant balance in type 1 diabetic children and adolescents have given conflicting results (4–7). The aim of this study was to determine whether serum hydroperoxides (reactive oxygen metabolites [ROMs]) as oxidative markers and plasma  $\alpha$ -tocopherol (vitamin E) and coenzyme Q10 as indexes of antioxidant capacity could be related to metabolic control in 75 unselected children, adolescents, and young adults with type 1 diabetes. ROMs are the first markers of oxidation and one of the most reliable indicators of oxidative stress. Vitamin E is an important chain-breaking antioxidant

factor controlling LDL oxidation. Coenzyme Q10 is an electron carrier–proton translocator in the respiratory chain and is an antioxidant factor by directly scavenging radicals or indirectly by regenerating vitamin E. ROMs were assayed using the kit d-ROMs test (Diacron), which is based on the Fenton reaction (8). Vitamin E was determined by reversed-phase high-performance liquid chromatography. Coenzyme Q10 was also determined by reversed-phase high-performance liquid chromatography, according to the method of Grossi et al. (9). Statistical significance was assessed using Student's *t* test and Pearson correlation index for normally distributed data and using Mann-Whitney and Spearman rank correlation for nonnormally distributed data. All results that were nominally significant at  $P < 0.05$  are indicated. Diabetic patients did not have different ROMs, vitamin E, and coenzyme Q10 levels from age-matched control subjects. Significant positive correlations were found between the following parameters: vitamin E and coenzyme Q10, coenzyme Q10 and HbA<sub>1c</sub>, and vitamin E and HbA<sub>1c</sub>. No correlation was observed between ROM levels and coenzyme Q10, vitamin E, or HbA<sub>1c</sub> values. Vitamin E and coenzyme Q10 values were higher in patients ( $n = 37$ ) with poor control (HbA<sub>1c</sub> >8%) than in those ( $n = 38$ ) with good control (HbA<sub>1c</sub> <8%) (vitamin E,  $25.2 \pm 9.5$  vs.  $20.9 \pm 4.6$ ,  $P = 0.044$ ; coenzyme Q10,  $1.12 \pm 0.56$  vs.  $0.82 \pm 0.33$ ,  $P = 0.012$ , respectively). The patients with retinal or renal complications ( $n = 19$ ) compared with those without had higher values of vitamin E ( $25.8 \pm 7.1$  vs.  $20.9 \pm 4.8$ ,  $P = 0.009$ ).

Therefore, in our patients vitamin E levels increased in all of the situations where an increase of oxidative stress was putative, i.e., in the presence of poor metabolic control and complications. This result is in disagreement with most of the data of the literature (5,7,10,11), but in agreement with a few studies (12,13). However, a further confirmation of this result is indirectly provided by our findings regarding coenzyme Q10. In fact, coenzyme Q10 levels, like vitamin E levels, are also higher in poorly controlled than in well-controlled patients and are positively correlated with HbA<sub>1c</sub> values. This finding is not surprising because these two antioxidants have strict physiological interrelationships and are positively inter-



correlated in both the patients and control subjects. On the other hand, it has already been demonstrated that high-glucose conditions produce an overexpression of intracellular antioxidant enzymes in human endothelial cells in culture (14) or in skin fibroblasts from diabetic patients (15) and that the decreased susceptibility to oxidative stress in diabetic rats is associated with an increase in mitochondrial glutathione and coenzyme Q contents (16). This effect seems to represent an adaptive response to increased oxidative stress. In very young patients, this response is high enough to neutralize the increase in reactive oxygen species. In fact, we found this unchanged in the blood of our patients.

SILVANA SALARDI, MD<sup>1</sup>  
STEFANO ZUCCHINI, MD<sup>1</sup>  
DANIELA ELLERI, MD<sup>1</sup>  
GABRIELE GROSSI, MC<sup>2</sup>  
ALBERTO M. BARGOSSO, AM, MD<sup>2</sup>  
STEFANO GUALANDI, PHD<sup>1</sup>  
ROBERTA SANTONI, MD<sup>1</sup>  
ALESSANDRO CICOGNANI, MD<sup>1</sup>  
EMANUELE CACCIARI, MD<sup>1</sup>

From the <sup>1</sup>Department of Pediatrics, University of Bologna, Bologna, Italy; and the <sup>2</sup>Central Laboratory of "S.Orsola-Malpighi" Hospital, Bologna, Italy.

Address correspondence to Prof. Silvana Salardi, Department of Pediatrics, Via Massarenti 11, 40138 Bologna, Italy. E-mail: salardi@med.unibo.it.

© 2004 by the American Diabetes Association.

## References

- Betteridge DJ: What is oxidative stress? *Metabolism* 49:3–8, 2000
- Baynes JW: Role of oxidative stress in development of complications in diabetes. *Diabetes* 40:405–412, 1991
- Hartnett ME, Stratton RD, Browne RW, Rosner BA, Lanhham RJ, Armstrong D: Serum markers of oxidative stress and severity of diabetic retinopathy. *Diabetes Care* 23:234–240, 2000
- Asayama K, Uchida N, Nakane T, Hayashibe H, Dobashi K, Amemiya S, Kato K, Nakazawa S: Antioxidants in the serum of children with insulin-dependent diabetes mellitus. *Free Radic Biol Med* 15:597–602, 1993
- Dominguez C, Ruiz E, Gussinye M, Carrascosa A: Oxidative stress at onset and in early stages of type 1 diabetes in children and adolescents. *Diabetes Care* 21:1736–1742, 1998
- Varvarovska J, Racek J, Stozicky F, Soucek J, Trefil L, Pomahacova R: Parameters of oxidative stress in children with type 1 diabetes mellitus and their relatives. *J Diabetes Complications* 17:7–10, 2003
- Willems D, Dorchy H, Dufrasne D: Serum antioxidant status and oxidized LDL in well-controlled young type 1 diabetic patients with and without subclinical complications. *Atherosclerosis* 137 (Suppl.): S61–S64, 1998
- Alberti A, Bolognini L, Macciantelli D, Caratelli M: The radical cation of N, N-Diethyl-para-phenyldiamine: a possible indicator of oxidative stress in biological samples. *Res Chem Intermed* 26:253–267, 2000
- Grossi G, Bargossi AM, Fiorella PL, Piazzi S, Battino M, Bianchi GP: Improved high-performance liquid chromatographic method for the determination of coenzyme Q10 in plasma. *J Chromatogr* 593: 217–226, 1992
- Krempf M, Ranganathan S, Ritz P, Morin M, Charbonnel B: Plasma vitamin A and E in type 1 (insulin-dependent) and type 2 (non insulin-dependent) adult diabetic patients. *Int J Vitam Nutr Res* 61:38–42, 1991
- Cinaz P, Hasanoglu A, Bideci A, Biberoglu G: Plasma and erythrocyte vitamin E levels in children with insulin dependent diabetes mellitus. *J Pediatr Endocrinol Metab* 12:193–196, 1999
- Hozumi M, Murata T, Morinobu T, Manago M, Kuno T, Tokuda M, Konishi K, Mingci Z, Tamai H: Plasma beta-carotene, retinol, and alpha-tocopherol levels in relation to glycemic control of children with insulin-dependent diabetes mellitus. *J Nutr Sci Vitaminol* 44:1–9, 1998
- Campoy C, Baena RM, Blanca E, Lopez-Sabater C, Fernandez-Garcia JM, Miranda MT, Molina-Font JA, Bayes R: Effects of metabolic control on vitamin E nutritional status in children with type 1 diabetes mellitus. *Clin Nutr* 22:81–86, 2003
- Ceriello A, dello Russo P, Amstad P, Cerutti P: High glucose induces antioxidant enzymes in human endothelial cells in culture: evidence linking hyperglycemia and oxidative stress. *Diabetes* 45: 471–477, 1996
- Ceriello A, Morocutti A, Mercuri F, Quagliari L, Moro M, Damante G, Viberti GC: Defective intracellular antioxidant enzyme production in type 1 diabetic patients with nephropathy. *Diabetes* 49:2170–2177, 2000
- Palmeira CM, Santos DL, Seiça R, Moreno AJ, Santos MS: Enhanced mitochondrial testicular antioxidant capacity in Goto-Kakizaki diabetic rats: role of coenzyme Q. *Am J Physiol Cell Physiol* 281:C1023–C1028, 2001

## Increased Oxidative Stress Is Associated With Serum Levels of Triglyceride, Insulin Resistance, and Hyperinsulinemia in Japanese Metabolically Obese, Normal-Weight Men

**M**etabolically obese, normal-weight (MONW) subjects (BMI <25 kg/m<sup>2</sup>) are characterized by an excess (≥100 cm<sup>2</sup> by abdominal computed tomography scanning) visceral fat area (VFA), insulin resistance, and hyperinsulinemia (1,2). The criteria for MONW subjects and the insulin resistance syndrome are very similar, and the pathophysiological events occurring in MONW subjects have recently been the focus of many investigators (1–4).

Several studies have reported the association of oxidative stress with insulin resistance and hyperinsulinemia in obese subjects (5,6). However, the degree of oxidative stress and its correlation with insulin resistance and insulin secretion have not yet been evaluated in MONW subjects.

The present study comprised 18 Japanese MONW (aged 34.7 ± 1.7 years, BMI 23.9 ± 0.3 kg/m<sup>2</sup>, and VFA 146.3 ± 5.8 cm<sup>2</sup> [means ± SE]) and 18 age-matched normal (BMI <25 kg/m<sup>2</sup> and VFA <100 cm<sup>2</sup>) men (aged 33.8 ± 1.4 years, BMI 21.9 ± 0.5 kg/m<sup>2</sup>, and VFA 59.3 ± 5.3 cm<sup>2</sup>).

According to the American Diabetes Association's diagnostic criteria, all subjects had normal glucose tolerance based on the 75-g oral glucose tolerance test (OGTT) (7).

The plasma levels of free 8-epi-prostaglandin F<sub>2</sub>α (8-epi-PGF<sub>2</sub>α) were measured as marker of oxidative stress using a commercially available enzyme immunoassay kit (Cayman Chemical, Ann Arbor, MI).

8-epi-PGF<sub>2</sub>α plasma levels in MONW men (40.4 ± 6.2 pg/ml; P < 0.01) were significantly increased compared with normal subjects (8.5 ± 1.5 pg/ml). The glucose infusion rates (index of insulin resistance during the euglycemic-hyperinsulinemic clamp study) in



monitoring. This study showed the expected fewer nocturnal hypoglycemic events, but the primary outcome was an improvement in glycemic control based on the HbA<sub>1c</sub> values. Patients HbA<sub>1c</sub> values were determined every 8 weeks, and insulin doses were titrated, with glargine adjusted based on morning fasting glucose values. If the HbA<sub>1c</sub> remained above goal, the intensity of home glucose monitoring was increased and bolus therapy was adjusted accordingly. In one-quarter of patients, the lunch bolus titration resulted in mid-afternoon hypoglycemia, and when reduced, the patients had elevated presupper glucose values. Patients who had an increase in their HbA<sub>1c</sub> and/or persistent elevation of presupper glucose despite titration of both bolus insulin and glargine insulin were then placed on twice-daily glargine injections. A split dose of glargine was given only after titration of glargine insulin resulted in morning hypoglycemia and/or persistent elevation of the afternoon blood glucose that could not be corrected with bolus titration.

Sixty-two subjects were using glargine insulin once daily, and the remaining 20 (24.2%) subjects required twice-daily therapy. The 24.2% of patients on split glargine were converted from once-daily glargine injections after an average of 289 ± 203 days (median 259). At that time, their HbA<sub>1c</sub> had deteriorated from an initial value of 7.9 ± 1.5 to 8.1 ± 1.4% (*P* = 0.16) and titration was limited by the symptoms outlined above. Subjects on split glargine did not differ from those subjects using once-daily glargine injections in regard to their age (*P* = 0.21), duration of diabetes (*P* = 0.21), baseline HbA<sub>1c</sub> (*P* = 0.91), presence of detectable C-peptide (*P* = 0.78), or the presence of microvascular complications: retinopathy (*P* = 0.37), nephropathy (*P* = 0.44), neuropathy (*P* = 0.30), or macrovascular complications (*P* = 0.88).

In the single-daily injection patients, the HbA<sub>1c</sub> improved significantly (from 7.8 to 7.3%, *P* = 0.01) after 476 ± 178 days on glargine insulin. The split glargine injection subjects also had an improvement in the HbA<sub>1c</sub> from 7.9 to 7.4% (*P* = 0.03) over a 3- to 6-month period. The ending HbA<sub>1c</sub> between groups was not significant (*P* = 0.80). The decrease from the mean starting HbA<sub>1c</sub> was identical between groups; however, a more sig-

nificant drop in the HbA<sub>1c</sub> from the time of split to the end of the study (8.1 to 7.4%) did reach statistical significance (*P* = 0.001). To achieve this improved glycemic control in these patients, 70% more glargine was required (44 ± 26 vs. 26 ± 13 units, *P* > 0.008).

In conclusion, in this prospective, nonblinded, nonrandomized, prospective study, one-quarter of type 1 diabetic patients required twice-daily glargine insulin injections to achieve acceptable glycemic control. The reason for this was that more glargine insulin could be safely and/or effectively used when split in this population. Regardless, type 1 diabetic patients on glargine insulin improved their glycemic control, as measured by the HbA<sub>1c</sub> values. Patients who do not achieve control after a titration period should receive split daily doses to achieve glycemic control.

This is the first study to demonstrate an improvement in HbA<sub>1c</sub> in type 1 diabetic subjects using basal-bolus therapy after conversion from basal NPH insulin to basal glargine insulin. Previous studies were not continued beyond 6 months, and the protocols restricted glargine to once-daily dosing (1–3). Using our study data to project the outcome, if all patients remained on single daily dosing, then the average HbA<sub>1c</sub> reduction would have been 0.3%, which is similar to other studies, and would not have been statistically significant.

ERIC S. ALBRIGHT, MD  
RENEE DESMOND, DVM, PHD  
DAVID S.H. BELL, MB

From the Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.

Address correspondence to David S.H. Bell, MD, University of Alabama at Birmingham, Department of Medicine, 1808 Seventh Ave. S., BDB 802, Birmingham, AL 35294. E-mail: dbell@endo.dom.uab.edu.

© 2004 by the American Diabetes Association.



References

1. Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, Mecca T: A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. *Diabetes Care* 23: 1666–1671, 2000
2. Rosenstock J, Park G, Zimmerman J, the US Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group: Basal insulin

glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. *Diabetes Care* 23: 1137–1142, 2000

3. Pieber TR, Eugene-Jolchine I, Derobert E, the European Study Group of HOE 901 in Type 1 Diabetes: Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. *Diabetes Care* 23: 157–162, 2000

COMMENTS AND RESPONSES

Memory Impairments Associated With Postprandial Hyperglycemia and Glycemic Control

Comment on Greenwood et al.

It was with interest that we read the study by Greenwood et al. (1), which investigated the impact of postprandial hyperglycemia on memory function in type 2 diabetic patients and demonstrated impaired memory function after carbohydrate ingestion. As they thoroughly discussed, the impact of glycemic control and transient hyperglycemia has been under investigation since the mid-1980s (2,3), with study results that are heterogeneous and not very conclusive. In fact, data from a study at our diabetes center (4) comprising 53 type 2 diabetic patients suggest that glycemic control has no influence on cognitive functioning, including memory (Auditory Verbal Learning Test), whereas patients with diabetic complications show lower performance.

One reason for the heterogeneity of results probably stems from the lack of consensus on which instruments to use for cognitive function assessment (5) and the usually small sample sizes. In this respect, unfortunately, Greenwood et al. did not use the standard versions of the tests for memory assessment but instead used instruments that were constructed of parallel forms and had obviously undergone profound changes, like omitting items. The precise nature of the test that

Downloaded from http://diabetesjournals.org/care/article-pdf/27/2/628/66117/628.pdf by guest on 05 October 2022

was applied is not described in their previous study either (6). Although they thoroughly addressed parallels of the versions used, the possible interference effects of several verbal memory tests used in a row are not discussed.

Taken together with the small sample size, the large interindividual variability of performance within the groups, and hence the fact that the adequacy of regression analysis is disputable, in our point of view the conclusions of Greenwood et al. are daring. Surely, neuropsychological effects of transient hyperglycemic excursions are worth being studied further, but concluding that ingestion of one-half bagel and grape juice leads to acute memory impairment seems, in our opinion, too far-reaching.

THOMAS KUBIAK, PHD<sup>1</sup>  
 NORBERT HERMANN, PHD<sup>1</sup>  
 MICHAEL PREIER, MA<sup>2</sup>  
 BERNHARD KULZER, MA<sup>3</sup>  
 THOMAS HAAK, MD<sup>1,3</sup>

From the <sup>1</sup>Research Institute of the Diabetes Academy, Diabetes Center Mergentheim, Bad Mergentheim, Germany; the <sup>2</sup>Department of Neuropsychology, Rehabilitation Clinic Staffelstein, Bad Staffelstein, Germany; the <sup>3</sup>Diabetes Clinic, Diabetes Center Mergentheim, Mergentheim, Germany.

Address correspondence to Dr. Thomas Kubiak, PhD, Forschungsinstitut der Diabetes Akademie Mergentheim (FIDAM), Diabetes Zentrum Mergentheim, Th.-Klotzbuecher-Str. 12, D-97980 Bad Mergentheim, Germany. E-mail: kubiak@diabeteszentrum.de.

© 2004 by the American Diabetes Association.

## References

- Greenwood CE, Kaplan RJ, Hebblethwaite S, Jenkins DJA: Carbohydrate-induced memory impairment in adults with type 2 diabetes. *Diabetes Care* 26:1961–1966, 2003
- Holmes CS: Metabolic control and auditory information processing at altered glucose levels in insulin-dependent diabetes. *Brain Cogn* 6:161–174, 1987
- Holmes CS: *Neuropsychological and Behavioral Aspects of Diabetes*. New York, Springer, 1990
- Hewer W, Mussell M, Rist F, Kulzer B, Bergis K: Short-term effects of improved glycemic control on cognitive function in patients with type 2 diabetes. *Gerontology* 49:86–92, 2003
- Strachan MW, Frier BM, Deary IJ: Cognitive assessment in diabetes: the need for consensus (Editorial). *Diabet Med* 14: 421–422, 1997
- Kaplan RJ, Greenwood CE, Winocur G,

Wolever TMS: Cognitive performance is associated with glucose regulation in healthy elderly persons and can be enhanced with glucose and dietary carbohydrates. *Am J Clin Nutr* 72:825–836, 2000

## Memory Impairments Associated With Postprandial Hyperglycemia and Glycemic Control

Response to Kubiak et al.

We thank Kubiak et al. (1) for their thoughtful appraisal of our study relating to memory response in adults with type 2 diabetes following carbohydrate ingestion (2). We agree entirely with their comment that the underlying origins of memory impairment in this population is poorly understood and that lack of consensus on standardized neuropsychologic testing procedures may, in part, be contributing to this confusion (3). Clearly, as Kubiak et al. point out, a major contributor to the variance in cognitive performance observed in this population is the high prevalence of other risk factors for cognitive decline, including cardiovascular disease, hypertension, and depression (4,5), making it challenging to isolate the potential contribution of diabetes per se.

We sought to explore cognitive function in adults with type 2 diabetes by perturbing the system through the administration of glucose, which is a treatment commonly used in studies of cognitive aging to explore the system's plasticity in the face of underlying age-related deficits (6,7). A major advantage of applying this approach to the type 2 diabetic population is that changes observed in response to the challenge were unlikely to be directly attributable to vascular complications. Our data provided evidence for cognitive deficits, primarily related to declarative memory function, following the ingestion of 50 g of glucose in the form of rapidly absorbed carbohydrate foods (bagel and juice). We then argued that this impairment was consistent with observations in healthy senior adults, in whom moderate elevations in

blood glucose resulted in memory enhancement and more extreme increases in blood glucose were associated with deficits (what is often referred to as an inverted-U dose-response relationship) (8). Based on this argument, we concluded that adults with type 2 diabetes likely responded to a glucose challenge in a manner comparable with that of older adults, with the caveat that they were more likely to attain levels of hyperglycemia associated with cognitive impairment given their underlying disease. Clearly, this is a conclusion requiring further verification.

One issue of concern raised by Kubiak et al. is that we include alternate versions, developed by us and others (9), of standardized neuropsychologic tests, although we apply these versions using standardized methodology. Our within-individual design, i.e., requiring multiple testing of subjects, necessitates their use. While we do not provide the precise details used to develop these alternate versions, we previously directed readers to those publications that we relied on to do so. Importantly, we have never stated or implied that these alternate versions should be used clinically from a diagnostic perspective; rather they are only used as experimental research tools. We agree that the use of these alternate versions potentially adds unwanted variance to our measures, but disagree that this detracts from the results obtained. Rather, the additional variance contributed by the use of alternate test versions makes it more, not less, difficult to observe change following glucose ingestion or associations between subject characteristics and performance levels. We address test version variability through the random allocation of different test versions both between and within subjects to uniformly distribute this additional variance (as much as possible) throughout the data, thereby minimizing potential bias associated with their use.

Another concern expressed was the limited number ( $n = 19$ ) of subjects in our study, which is in essence an extension of those concerns related to test version variability. While not commented on in the original publication, this sample size was based on power analyses drawing on our results in healthy senior adults receiving glucose in the form of carbohydrate foods and including the same alternate versions of the neuropsychologic tests (9). Thus we believe our study to be statistically sound. Nevertheless, as

with all studies, the extension of the results to the broader population is complicated by the fact that subjects willing to participate in experimental procedures are somewhat unique and, in this sense, differ from the more heterogeneous population typically observed in clinical practice—a factor of importance in all studies drawing on human volunteers.

Finally, Kubiak et al. comment on concerns related to interference when multiple tests probing declarative memory are used. This factor is not discussed in this work but is addressed by us previously (9) in studies conducted on healthy senior adults. This comment raises multiple issues of interest. The first is that the exact nature of the declarative memory deficits observed in adults with type 2 diabetes remains largely unexplored. Clearly, multiple components of cognitive function are recruited and contribute to performance on end measures of delayed verbal recall; yet the precise deficit, potentially including interference and inhibitory control, remains largely unexplored. Admittedly, we observed deficits in our study on the second, not the first, verbal recall test used, thus raising the possibility that interference is an important contributor and one requiring further exploration. Yet this does not detract from the fact that performance on this second test was poorer when subjects were tested following carbohydrate ingestion compared with when they were tested following placebo (water) ingestion. The second issue relating to the comment by Kubiak et al. is the degree to which one controls for external factors influencing cognitive performance. Clearly, our data suggest that the fed/fasted state of the individual may be an important contributor to observed variance. Similarly, time of day of testing is another recognized contributor to within-individual variance in cognitive function and shifts in peak performance times occur in states, such as aging, wherein disruptions to circadian sleep rhythms are apparent (10). This is clearly a pattern disruption to which adults with type 2 diabetes may be especially vulnerable. Yet rarely do authors address when during the day testing occurred and whether a fixed time of day was used, as we did in our studies. All of these factors are likely important and contribute to the “unexplained” variance in regression models. Some will view this as exciting opportunities for new exploration,

whereas others will see this as reason to discount “explained” variance in function.

Certainly, it is essential that as we wade through conflicting data regarding the origins of cognitive deficits in adults with type 2 diabetes, be they primarily or secondarily associated with the high prevalence of other risk factors in this population, that we not lose sight of the shared and common interest, which is helping those with type 2 diabetes prevent or minimize their risk of cognitive dysfunction. Kubiak et al. state that we were daring to conclude that transitory food-induced hyperglycemic episodes could be associated with acute cognitive deficits in this population. We continue to stand by our conclusions but recognize that further studies will either support or refute our conclusions.

CAROL E. GREENWOOD, PHD<sup>1,2,3</sup>  
 RANDALL J. KAPLAN, PHD<sup>1,2</sup>  
 STACEY HEBBLETHWAITE, BSC<sup>1</sup>  
 DAVID J.A. JENKINS, MD, PHD<sup>1,4,5</sup>

From the <sup>1</sup>Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; the <sup>2</sup>Department of Food and Nutrition Services, Baycrest Centre for Geriatric Care, Toronto, Ontario, Canada; the <sup>3</sup>Kunin-Lunenfeld Applied Research Unit, Baycrest Centre for Geriatric Care, Toronto, Ontario, Canada; the <sup>4</sup>Clinical Nutrition and Risk Modification Centre, St. Michael's Hospital, Toronto, Ontario, Canada; and the <sup>5</sup>Division of Endocrinology and Metabolism, St. Michael's Hospital, Toronto, Ontario, Canada.

Address correspondence to Carol Greenwood, Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada M5S 3E2. E-mail: carol.greenwood@utoronto.ca.

© 2004 by the American Diabetes Association.

#### References

1. Kubiak T, Hermanns N, Preier M, Kulzer B, Haak T: Memory impairments associated with postprandial hyperglycemia and glycemic control: comment on Greenwood et al. (Letter). *Diabetes Care* 27:633–634, 2004
2. Greenwood CE, Kaplan RJ, Hebblethwaite S, Jenkins DJA: Carbohydrate-induced memory impairment in adults with type 2 diabetes. *Diabetes Care* 26:1961–1966, 2003
3. Strachan MW, Frier BM, Deary IJ: Cognitive assessment in diabetes: the need for consensus (Editorial). *Diabet Med* 14: 421–422, 1997
4. Strachan MW, Deary IJ, Ewing FM, Frier BM: Is type II diabetes associated with an increased risk of cognitive dysfunction? A

critical review of published studies. *Diabetes Care* 20:438–445, 1997

5. Stewart R, Liolitsa D: Type 2 diabetes mellitus, cognitive impairment and dementia. *Diabet Med* 16:93–112, 1999
6. Gold P: Glucose modulation of memory storage processing. *Behav Neural Biol* 45: 342–349, 1986
7. Messier C, Tsiakas M, Gagnon M, Desrochers A, Awad N: Effect of age and glucose regulation on cognitive performance. *Neurobiol Aging* 24:985–1003, 2003
8. Parsons MW, Gold PE: Glucose enhancement of memory in elderly humans: an inverted-U dose-response curve. *Neurobiol Aging* 13:401–404, 1992
9. Kaplan RJ, Greenwood CE, Winocur G, Wolever TMS: Cognitive performance is associated with glucose regulation in healthy elderly persons and can be enhanced with glucose and dietary carbohydrates. *Am J Clin Nutr* 72:825–836, 2000
10. Li KZ, Hasher L, Jonas D, Rahhal TA, May CP: Distractibility, circadian arousal, and aging: a boundary condition? *Psychol Aging* 13:574–583, 1998

## Off-Loading in Trials in Neuropathic Diabetic Foot Ulceration

No, it's not time for a paradigm shift

Professor Boulton and Dr. Armstrong (1) argued recently that “all future trials of therapy should use a nonremovable off-loading device.” In doing so, they betray a failure to understand how the structure of trials must be determined by their purpose: those designed to determine the efficacy (“Can it work in ideal circumstances?”) may differ from those designed to determine effectiveness (“Does it work in practice?”). Two factors that underlie the capacity of a controlled trial to demonstrate efficacy are 1) the effect, or lack of it, of the intervention and 2) the effect of the control. Boulton and Armstrong concluded (with no evidence) that the failure of Veves et al. (2) to demonstrate any benefit of Promogran was “likely” to be the result of a failure to standardize off-loading techniques. Another interpretation is that the product is comparatively ineffective in routine practice.

The classical total contact cast (TCC) does not have a dressing window, and so how can it be used in trials of dressings

and applications designed to be changed more often than the off-loading device? A TCC, but not their modified walker, can be modified by incorporating a dressing window, but dressing windows have their problems. If too small, they limit the ability to clean and dress the wound properly. If too large, they limit the effectiveness of off-loading by allowing the ulcerated area to prolapse.

Crucially, however, Boulton and Armstrong fail to satisfactorily address the questions of acceptability and safety. They acknowledge that TCCs have adverse effects and suggest that these may be overcome with their modified walker, but admit that relevant trials have not been completed. In truth, many people find nonremovable devices unacceptable, with reasons that include secondary ulceration of the index foot, abrasions on the contralateral foot, unsteadiness (especially in the elderly, those with postural hypotension or impaired proprioception), and falls from tripping, not to mention the ease—or lack of it—with which patients can shower or take a bath. Trials of nonremovable off-loading devices may be critically biased by population selection.

In conclusion, we emphasize our enormous respect for the work undertaken by Boulton and Armstrong but think that their arguments are simply not justified. The recent Cochrane review of off-loading (3) concluded that “there is very limited evidence of the effectiveness of total contact casts” and highlighted the fact that there has been no comparison undertaken between TCC and Scotchcast (or equivalent) removable boots, which are widely used in many countries. The TCC is an option, but not sine qua non in either clinical practice or future trials.

WILLIAM J. JEFFCOATE, MRCP<sup>1</sup>  
FRANCES L. GAME, MRCP, MRCPATH<sup>1</sup>  
PATRICIA E. PRICE, PHD<sup>2</sup>

From the <sup>1</sup>Department of Diabetes and Endocrinology, Foot Ulcer Trials Unit, City Hospital, Nottingham, U.K.; and the <sup>2</sup>Wound Healing Research Unit, Cardiff Medicenter, Heath Park, Cardiff, U.K.

Address correspondence to Dr. W.J. Jeffcoate, Foot Ulcer Trials Unit, Department of Diabetes and Endocrinology, City Hospital, Nottingham NG5 1PB, U.K. E-mail: jeffcoate@bigfoot.com.

© 2004 by the American Diabetes Association.

References

1. Boulton AJM, Armstrong DG: Trials in neuropathic diabetic foot ulceration: time

for a paradigm shift? (Editorial). *Diabetes Care* 26:2689–2690, 2003

2. Veves A, Sheehan P, Pham HT: A randomized controlled trial of promogran vs standard treatment in the management in the management of diabetic foot ulcers. *Arch Surg* 137:822–827, 2002
3. Spencer S: Pressure relieving interventions for preventing and treating diabetic foot ulcers. *Cochrane Database Syst Rev* 3:CD002302, 2000

## Off-Loading in Trials of Neuropathic Diabetic Foot Ulceration

Further evidence of the need for a paradigm shift

We are happy that our recent editorial (1) stimulated interest from other experts in the diabetic foot. However, we find ourselves in disagreement with the letter by Jeffcoate and Game in this issue of *Diabetes Care* (2) in several respects. They suggest that our editorial betrays “a failure to understand how the structure of trials must be determined.” Surely, this cannot be the case. Any trial assessing dressings, drugs, or constructs should be designed to provide the maximum opportunity for the product to demonstrate efficacy by removing all possible confounding variables. As we have recently demonstrated (3), those patients provided with removable cast walkers only wear their device for 28% of activity daily, so we proposed that future trials should therefore standardize off-loading, preferably using a nonremovable device. As off-loading in the trial of promogran (4) was “left to the individual center,” we stand by our assessment that a likely explanation of the failure to demonstrate efficacy was related to a failure to standardize off-loading.

Having demonstrated the efficacy of any new product, it then behooves us to translate the results into clinical practice. Here we agree with Jeffcoate and Game that not all patients can tolerate casts; however, our experience to date suggests that the instant total contact cast (TCC) is better tolerated by patients than the TCC (5). (The instant TCC is a removable cast walker rendered nonremovable by wrapping it with cast material.) Further studies on this will be published in 2004. Rather

than stating that many patients cannot tolerate nonremovable devices, surely research should be directed at improving the design of such casts to make them more safe and acceptable. We suggest that the failure to develop satisfactory off-loading in recent years is responsible for the poor results of trials of potential new therapies for plantar ulcers.

Jeffcoate and Game then assert that TCCs do not have dressing windows. Coincidentally, in the very next issue of *Diabetes Care*, Ha Van et al. (6) describe a TCC incorporating just such a window.

Further support for our position appears in several articles published in the months since the appearance of our editorial. In addition to describing the incorporation of a dressing window into a nonremovable cast, Ha Van et al. reported that only 10% of patients complied with the removable off-loading device in their studies, suggesting that the 28% reported in our study (3) was likely realistic, if not optimistic. Secondly, Caravaggi et al. (7) demonstrated that trials of new dressings could be successfully executed using a nonremovable cast. Finally, Piaggese et al. (8) provide pivotal histological evidence strongly demonstrating the importance of adequate off-loading. It is now clear why so many trials have failed to demonstrate efficacy in recent years. Hence, we reiterate the need for a paradigm shift in the design of future clinical trials of putative therapies for plantar neuropathic ulcers.

ANDREW J.M. BOULTON, MD, FRCP<sup>1</sup>  
DAVID G. ARMSTRONG, MSC, DPM<sup>2</sup>

From the <sup>1</sup>Diabetes Research Unit, University of Miami, Miami, Florida; and the <sup>2</sup>Department of Surgery, Tucson Veterans Affairs Medical Center, Tucson, Arizona.

Address correspondence to Andrew J.M. Boulton, MD, FRCP, Diabetes Research Unit, University of Miami, P.O. Box 016960 (D110), Miami, FL 33101. E-mail: aboulton@med.miami.edu.

© 2004 by the American Diabetes Association.

References

1. Boulton AJM, Armstrong DG: Trials in neuropathic diabetic foot ulcers: time for a paradigm shift? (Editorial). *Diabetes Care* 26:2689–2690, 2003
2. Jeffcoate WJ, Game FL: Off-loading in trials in neuropathic diabetic foot ulceration: no, it's not time for a paradigm shift (Letter). *Diabetes Care* 27:635–636, 2004
3. Armstrong DG, Lavery LA, Kimbriel HR, Nixon BP, Boulton AJ: Activity patterns of patients with diabetic foot ulceration: pa-

tients with active ulceration may not adhere to a standard pressure off-loading regimen. *Diabetes Care* 26:2595–2597, 2003

4. Veves A, Sheehan P, Pham HT: A randomized controlled trial of promogran vs standard treatment in the management of diabetic foot ulcers. *Arch Surg* 137:822–827, 2002
5. Armstrong DG, Short B, Espensen EH, Abu-Rumman PL, Nixon BP, Boulton AJ: Technique for fabrication of an “instant total-contact cast” for treatment of neuropathic diabetic foot ulcers. *J Am Podiatr Med Assoc* 92:405–408, 2002
6. Ha Van G, Siney H, Hartmann-Heurtier A, Jacqueminet S, Greau F, Grimaldi A: Nonremovable, windowed, fiberglass cast boot in the treatment of diabetic plantar ulcers: efficacy, safety, and compliance. *Diabetes Care* 26:2848–2852, 2003
7. Caravaggi C, DeGiglio R, Pritelli C, Sommaria M, Dalla Noce S, Faglia E, Mantero M, Clerici G, Fratino P, Morabito A: HYAFF 11–based autologous dermal and epidermal grafts in the treatment of non-infected diabetic plantar and dorsal foot ulcers: a prospective, multicenter, controlled, randomized clinical trial. *Diabetes Care* 26:2853–2859, 2003
8. Piaggese A, Viacava P, Rizzo L, Naccarato G, Baccetti F, Romanelli M, Zampa V, Del-Prato S: Semiquantitative analysis of the histopathological features of the neuropathic foot ulcer: effect of pressure relief. *Diabetes Care* 26:3123–3128, 2003

## C-Reactive Protein and Glycemic Control in Adults With Diabetes

Response to King et al.

King et al. (1) recently suggested an association between glycemic control and systemic inflammation, i.e., between HbA<sub>1c</sub> levels and highly sensitive C-reactive protein (hsCRP) levels, based on data from 1,018 participants in the Third National Health and Nutrition Examination Survey. This report prompted us to search for a similar association in our clinical practice.

Since hsCRP levels can be lowered by statins, thiazolidinediones (TZDs), and anti-inflammatory drugs, we first looked at 64 C-peptide–negative type 1 diabetic patients whose only medication was insu-

lin and found no association ( $r = 0.0748$ ,  $P = 0.28$ ) between HbA<sub>1c</sub> levels and hsCRP. With this negative association, we investigated 108 C-peptide–positive type 2 diabetic patients, all of whom were on a statin, an aspirin, and a TZD, to see whether there was an association between hsCRP and HbA<sub>1c</sub> in this homogenous group on maximal hsCRP-lowering therapy. The association was again negative, with an  $r$  value of 0.0424 and a  $P$  value of 0.78.

Why then did King et al. find an association of HbA<sub>1c</sub> with hsCRP and we did not? We believe that King et al.'s association was with insulin resistance and not hyperglycemia. An association of insulin resistance and hsCRP has been well documented, and theoretically at least, the greater the insulin resistance the worse the glycemic control and, conversely, the higher the glucose the greater the insulin resistance (glucotoxicity). In our group of type 2 diabetic patients who were all on a TZD, insulin resistance should be maximally treated so that if hyperglycemia did affect the hsCRP, its effects would not be confounded by the effects of insulin resistance.

That insulin resistance was not a factor in the King et al. study could be concluded from the inclusion of fasting insulin levels in the regression model. When diabetic subjects are treated with insulin, insulin secretagogues, or insulin sensitizers, the effectiveness of a fasting serum insulin level as a marker for insulin resistance is negated and the conclusion that insulin resistance was eliminated as a factor nullified.

To resolve this problem of differing conclusions from an epidemiological cross-sectional study and a retrospective cross-sectional clinical study, a prospective longitudinal study should be performed. An ideal study would be of type 1 diabetic patients at onset who are clinically free of infection, with measurements of hsCRP being performed before insulin therapy and 2 months later when they are well controlled in the honeymoon period. This is of clinical importance because if hsCRP levels are elevated due to hyperglycemia, then hsCRP levels should only be measured when glycemia is controlled to avoid unnecessary prescribing.

DAVID S.H. BELL, MB, FACE  
ROBERT W. HARDY, PHD  
RENEE DESMOND, PHD

From the Department of Medicine, University of Alabama Medical School, Birmingham, Alabama.

Address correspondence to David S.H. Bell, MD, University of Alabama at Birmingham, Department of Medicine, 1808 Seventh Ave. S., BDB 802, Birmingham, AL 35294. E-mail: dbell@endo.dom.uab.edu.

© 2004 by the American Diabetes Association.

### References

1. King DE, Mainous AG, Buchanan TA, Pearson WS: C-reactive protein and glycemic control in adults with diabetes. *Diabetes Care* 26:1535–1539, 2003
2. Ford ES: Body mass index, diabetes, and C-reactive protein among U.S. adults. *Diabetes Care* 22:1971–1977, 1999

## C-Reactive Protein and Glycemic Control in Adults With Diabetes

Response to Bell, Hardy, and Desmond

We thank Bell, Hardy, and Desmond (1) for their comments regarding our recent article (2), and we appreciate the opportunity to respond to the issues they have raised. Based on their analysis of two groups of patients in their practice, Bell, Hardy, and Desmond question whether there is an association between CRP and glycemic control. Several possible explanations exist for the difference in our findings. First, we used a nationally representative population-derived database that may be more diverse than the one used by them. Second, we specifically excluded people on anti-inflammatory and cholesterol-lowering medications, precisely because the use of such individuals is likely to confound the relationship between C-reactive protein (CRP) and HbA<sub>1c</sub> (insulin-sensitizing drugs were not widely available at the time of the study [1988–1994]). Another reason for the difference in our findings could be our ability to account for several other factors that might confound or mask the relationship, including age, race, sex, BMI, smoking, length of time with diabetes, and fasting insulin levels. Further supporting our

findings, other researchers have found a similar association between CRP and HbA<sub>1c</sub> in nondiabetic individuals (3).

Bell, Hardy, and Desmond correctly note the limitation of fasting insulin level as a measure of insulin resistance. However, their conclusion that CRP is related to insulin resistance rather than glycemia may also be premature, since the term insulin resistance is a very general one that includes several possible underlying mechanisms. Our report did not address specific mechanisms for the association we found, but instead called for more research to further delineate the nature of the association. We agree with Bell, Hardy, and Desmond that more definitive

prospective and interventional studies are needed to investigate the association between CRP and glycemia, as we urged in our article.

DANA E. KING, MD<sup>1</sup>  
 ARCH G. MAINOUS, III, PHD<sup>1</sup>  
 THOMAS A. BUCHANAN, MD<sup>2</sup>  
 WILLIAM S. PEARSON, MHA<sup>1</sup>

From the <sup>1</sup>Department of Family Medicine, Medical University of South Carolina, Charleston, South Carolina; and the <sup>2</sup>General Clinical Research Center, University of Southern California School of Medicine, Los Angeles, California.

Address correspondence to Dana E. King, MD, Medical University of South Carolina, Department of Family Medicine, 295 Calhoun St., Charleston, SC 29425. E-mail: kingde@musc.edu.

© 2004 by the American Diabetes Association.



#### References

1. Bell DSH, Hardy RW, Desmond R: C-reactive protein and glycemic control in adults with diabetes (Letter). *Diabetes Care* 27:637, 2004
2. King DE, Mainous AG, Buchanan TA, Pearson WS: C-reactive protein and glycemic control in adults with diabetes. *Diabetes Care* 26:1535–1539, 2003
3. Wu T, Dorn JP, Donahue RP, Sempos CT, Trevisan M: Associations of serum C-reactive protein with fasting insulin, glucose, and glycosylated hemoglobin: the Third National Health and Nutrition Examination Survey, 1988–1994. *Am J Epidemiol* 155:65–71, 2002